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ABSTRACT 14 
Vaginal rings (VRs) are flexible, torus-shaped, polymeric devices designed to sustain delivery of 15 
pharmaceutical drugs to the vagina for clinical benefit. Following first report in a 1970 patent 16 
application, several steroid-releasing VR products have since been marketed for use in hormone 17 
replacement therapy and contraception. Since 2002, there has been growing interest in the use of 18 
VR technology for delivery of drugs that can reduce the risk of sexual acquisition of human 19 
immunodeficiency virus type 1 (HIV-1), the causative agent of acquired immunodeficiency 20 
syndrome (AIDS). Although no vaginally-administered product has yet been approved for HIV 21 
reduction/prevention, extensive research efforts are continuing and a number of VR devices 22 
offering sustained release of so-called ‘HIV microbicide’ compounds are currently being 23 
evaluated in late-stage clinical studies. This review article provides an overview of the published 24 
scientific literature within this important field of research, focusing primarily on articles 25 
published within peer-reviewed journal publications. Many important aspects of microbicide-26 
releasing VR technology are discussed, with a particular emphasis on the technological, 27 
manufacturing and clinical challenges that have emerged in recent years.  28 
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1. Introduction 119 
In 1983, following two years of increasing number of reported cases in the United States (U.S) of 120 
severe immune deficiency among gay men and infants receiving blood transfusions, scientists 121 
first identified the human immunodeficiency virus (HIV) as the retrovirus that causes acquired 122 
immune deficiency syndrome (AIDS). By 1987, three biomedical strategies were at the forefront 123 
of developments to treat or prevent HIV infection. In March 1987, the U.S. Food and Drug 124 
Administration (FDA) approved the first antiretroviral (ARV) drug, zidovudine (AZT), for 125 
treatment of HIV by reducing replication of the virus. In August 1987, the FDA sanctioned the 126 
first human testing of a candidate vaccine against HIV. Later the same year, the FDA declared 127 
HIV prevention as a new indication for male condoms.    128 
 129 
Fast-forward three decades and, despite the tremendous advancements in our scientific 130 
knowledge and understanding, the HIV/AIDS pandemic remains one of the most serious global 131 
public health crises of our time. The latest (2014) global statistics for HIV/AIDS estimate 37 132 
million people living with HIV, 2 million new infections annually, and 1.2 million deaths in 2014 133 
from AIDS-related illnesses [1]. Sub-Saharan Africa remains the hardest hit region, accounting 134 
for more than 70% of people presently living with HIV/AIDS. 135 
 136 
Development of a safe and effective HIV vaccine has proven very difficult. Ideally, an effective 137 
HIV vaccine should induce powerful and durable immunity capable of preventing infection in 138 
healthy individuals and/or reducing viral replication and viral load in infected individuals with 139 
the aim of slowing or halting disease transmission and progression. To date, more than 250 140 
clinical trials of HIV vaccine candidates have been completed or are presently being conducted; 141 
only six of these candidates have reached late-stage clinical testing, and none have demonstrated 142 
significant efficacy [2]. 143 
 144 
With consistent and correct use, male latex condoms can reduce the risk of heterosexual 145 
transmission of HIV by more than 70% [3–5]. However, despite widespread and often aggressive 146 
promotion, condom use has not reached a sufficiently high level to impact rates of HIV 147 
acquisition in Sub-Saharan Africa. One reason lies with gender-power imbalances, resulting in 148 
women not always being able to negotiate condom use with male partners. For example, African 149 
men are more likely to refuse condom use when there are large differences in age between them 150 
and their female partners, if they are married, when they have multiple sexual partners, and where 151 
there is no communication about HIV/AIDS between them and their partners [6]. Female 152 
condoms, widely promoted as a female-controlled alternative to male condoms, have failed to 153 
gain acceptance, despite the introduction of new types [7–10]. 154 
 155 
On a more positive note, increased access to highly active antiretroviral therapy (HAART) means 156 
that an AIDS diagnosis is no longer a death sentence for millions of people. Today, 28 FDA-157 
approved ARV drugs are available for treatment of HIV-1 infections [11]. These drugs are 158 
mainly classified into six distinct types based on their mechanism of action: nucleoside-analog 159 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 160 
(NNRTIs), integrase inhibitors, protease inhibitors (PIs), fusion inhibitors and co-receptor 161 
antagonists. As of March 2015, 15 million people living with HIV, including 11 million in Sub-162 
Saharan Africa, were accessing life-saving HAART, up from 13.6 million in June 2014 and only 163 
300,000 in 2002, exceeding the targets set as part of the Millennium Development Goals [1]. 164 
Meanwhile, the number of people newly infected with HIV has fallen by 35% since 2000 and 165 
global deaths due to AIDS have declined 42% since the peak in 2004. With this halting and 166 
reversing the spread of HIV/AIDS, and with continued effort and investment, the world is 167 
seemingly on track to end the AIDS pandemic by 2030 [1]. 168 
 169 
It is widely accepted that ARV treatment alone will not be able to curtail the HIV/AIDS 170 
pandemic.  In the continued absence of an effective HIV vaccine, there is greater optimism about 171 
the clinical potential of HIV microbicides. HIV microbicides are pharmaceutical formulations 172 
administered vaginally (or rectally) to reduce sexual transmission of the virus. The concept of an 173 
HIV microbicide was first described in a 1990 commentary piece entitled ‘HIV Prevention: The 174 
Need for Methods Women Can Use’ [12]. Recognizing the limitations of behavior-modification 175 
strategies and use of condoms in reducing HIV infection rates, Stein strongly advocated research 176 
into new methods that women could use to prevent vaginal transmission of HIV. Of course, these 177 
‘topical virucides’, as they were then called, would have to be acceptable to women in terms of 178 
convenience of use, safety and cost, as well as highly effective against the virus. A number of 179 
surfactant-type vaginal microbicides were tested in women during the 1990s (Figure 1), including 180 
a compound called nonoxynol-9 (N9). Most of these studies not only failed to protect women 181 
against HIV infection, but some actually increased HIV infection rates compared with a placebo 182 
product. Surfactant-type microbicides were subsequently abandoned. Next, the focus switched to 183 
various polymer molecules (Figure 1), whose negatively charged functional groups were shown 184 
in laboratory experiments to prevent the virus attaching to the immune cells. However, as with 185 
the surfactants, these polymer-based microbicides failed to provide protection in clinical studies, 186 
and once again, some increased the risk of infection. 187 
 188 
The past five years has seen the microbicide field focus almost exclusively on more conventional 189 
small molecule ARV drugs, the same or similar drugs to those used since the 1980s for treating 190 
people already infected with HIV. A breakthrough came in 2010 when the first results emerged 191 
from the CAPRISA 004 trial [13]. For the first time, a vaginally-administered ARV gel product 192 
was shown to provide significant protection against HIV infection. A summary timeline 193 
describing key moments, and particularly major clinical activities, in the development of HIV 194 
microbicides is presented in Figure 1.  195 
 196 
2. Microbicide-releasing vaginal rings 197 
The application of VR technology, first described and widely reported during the 1970s for 198 
vaginal delivery of contraceptive hormones (see Section 2.1), to the formulation of HIV 199 
microbicides was first proposed publicly at the 2002 Microbicides Conference in Antwerp, 200 
Belgium [14]. At that time, the microbicide field was almost exclusively focused on aqueous 201 
vaginal gel formulations containing non-specific microbicide candidates, such as the surfactant 202 
N9 and various polymer molecules (see Section 2.6.1), reflecting a lack of engagement and 203 
interest in the challenges of HIV prevention by basic scientists with expertise in drug design and 204 
formulation development. Today, semi-solid drug products, including gels, are the most common 205 
formulation type for vaginal drug administration. For example, of the 24 vaginal products 206 
currently marketed in the UK, 16 are either gels or creams, and only two are VR devices 207 
(Estring® and Nuvaring®). Since the beginning of the new millennium, a diverse range of 208 
formulation strategies for HIV microbicides has been investigated, including films, tablets, 209 
diaphragms, capsules, freeze-dried tablets, and nanoparticles [15]. However, ongoing concerns 210 
over poor user adherence associated with coitally-dependent gel products and a strong preference 211 
for formulations that offer continuous delivery of microbicide(s) over extended time periods has 212 
resulted in a very significant shift in focus towards VR-based products that offer 213 
sustained/controlled release [15–17]. 214 
 215 
The first journal article describing a microbicide-releasing VR for HIV prevention was published 216 
in 2003 [18]. The matrix-type silicone elastomer ring contained the non-ionic surfactant N9, at 217 
that time a lead HIV microbicide candidate although soon to be overshadowed by evidence that 218 
in gel format it damaged the vaginal epithelium resulting in increased risk of HIV acquisition 219 
[19]. Two years later, the continuous, zero-order release of TMC120 (later renamed dapivirine, 220 
DPV) over 71 days from a core-type (also commonly referred to as ‘reservoir-type’) silicone 221 
elastomer VR [20] was described. This reservoir-type VR design was very similar to the 222 
marketed VR products Estring® and Femring®.   223 
 224 
2.1. Historical overview of vaginal ring technology 225 
VRs are flexible, torus-shaped polymeric devices designed to provide sustained, long-term 226 
delivery of pharmaceutical agents to the vagina for clinical benefit. The first VR device for drug 227 
delivery was reported in a US patent application filed on 4th January 1968 and subsequently 228 
awarded on 8th December 1970 to the UpJohn Company [21]. These polymeric drug delivery ring 229 
devices, fabricated using silicone (polydimethylsiloxane, PDMS) elastomers, focused primarily 230 
on contraception and hormone replacement therapies (HRT). Since their inception in the 1960s, 231 
numerous ring designs containing various drug combinations have been proposed, tested and 232 
documented in the literature [21–26]. 233 
 234 
The first clinical trials of a VR were performed in the 1970s for the contraceptive progestin 235 
medroxyprogesterone acetate [23]. However, this early ring design, which consisted of a metal 236 
spring over-molded by a silicone sheath (Figure 2A) caused numerous problems including 237 
erosion and ulceration of the vaginal epithelium [22]. Although first generation VR products 238 
were clinically effective, the devices were extremely rigid and inflexible making them prone to 239 
expulsion during normal daily activities. An early study of a levonorgestrel (LNG)-releasing ring 240 
device reported that 48 out of 139 female participants developed surface lesions/ulcerations, 241 
chronic inflammation and thinning of the vaginal epithelium [27]. These adverse effects were 242 
most likely the result of a combination of factors including (i) the geometry of the ring, (ii) the 243 
inflexible nature of the device causing localised pressure on the vaginal epithelium and (iii) 244 
epithelial thinning effects caused by the hormonal contraceptive agent. As a result thinner, more 245 
flexible, non-irritating VR designs with optimised geometries (outer diameter ranging from 50 to 246 
58 mm; cross-sectional diameter ranging from 4 to 9.5 mm) were developed [28–32]. 247 
 248 
Despite initial enthusiasm for these new controlled-release VR devices, formulation issues and 249 
concerns regarding the safety of long-acting steroid releasing rings saw many ring development 250 
studies discontinued. To date, five VR products have reached marked – Estring® (Pfizer Inc., 251 
USA) and Femring® (Actavis, UK) for hormone replacement therapy, NuvaRing® (Merck & Co, 252 
USA), Progering® (Laboratorios Silesia, Chile) for contraception, and Fertiring® (Laboratorios 253 
Silesia, Chile) for both pregnancy maintenance during in vitro fertilization and hormone 254 
replacement therapy in menopausal women. Clinical studies have shown a high degree of 255 
acceptability for VR devices over conventional semi-solid vaginal gels and creams [16,33–36]. 256 
 257 
Historically, silicone elastomers were the polymer of choice for fabrication of VR devices [20–258 
23,37,38] owing to their lightweight, flexible nature and excellent biocompatibility. However, as 259 
VR designs have become increasingly more sophisticated a range of polymeric materials 260 
including poly(ethylene-co-vinyl acetate) (EVA) [39–41] and more recently thermoplastic 261 
polyurethanes (TPU) have been used for the manufacture of these ring devices [17,26,42–44]. 262 
Materials for ring fabrication are discussed in more detail in Section 2.3. 263 
 264 
2.2. Types of vaginal rings for microbicide delivery 265 
The application of VR technology to the delivery of HIV microbicide molecules having a broad 266 
range of physicochemical properties has led to very considerable innovation in new ring designs 267 
(Figure 2). Before 2006, VR designs being considered for microbicide delivery were mostly 268 
based on conventional matrix and reservoir-type systems, reflecting the design types used in 269 
marketed ring devices. However, the highly hydrophobic properties of EVA and silicone 270 
elastomer that had thus far proved successful for the formulation of hydrophobic, steroid drugs 271 
for estrogen replacement therapy and contraception were often not able to offer suitable 272 
permeation characteristics for many lead microbicide candidates. Also, microbicides in general, 273 
and ARVs in particular, do not generally possess the same clinical potency as steroid hormones, 274 
such that much larger doses (in the form of increased daily release rates) are required for efficacy. 275 
For example, while DPV has very similar physicochemical characteristics (e.g. molecular weight, 276 
partition coefficient, water solubility, etc.) to many steroid molecules, TFV and TDF are 277 
significantly more hydrophilic and therefore less capable of achieving clinically significant 278 
release rates from conventional VR designs that rely on permeation from hydrophobic elastomers 279 
as the primary mechanism of release. As a result, a raft of new ring designs – still largely based 280 
around silicone elastomer, EVA and TPU materials (see Section 2.3) – has emerged aimed at 281 
overcoming this permeation barrier, including segmented matrix, multi-core, segmented 282 
reservoir, rod/tablet insert, core-matrix and pod insert rings (Figure 2). A major impetus for 283 
continued innovation in ring design has been the growing interest in combination microbicide 284 
[45] and multipurpose prevention technology products [46–49] (see Section 2.8), for which 285 
release characteristics need to be individually tailored for each drug molecule. The release 286 
mechanisms that govern these new designs are discussed in Section 2.4.   287 
 288 
2.3. Material selection 289 
Drug-releasing VRs, comprising a combination of drug and device, are formally classified as 290 
combination products as defined in FDA documentation 21 CFR 3.2(e). Most commonly in VRs, 291 
the drug component takes the form of a potent ARV molecule and the device component 292 
comprises a polymeric ring device. Because combination products involve components that 293 
would normally be regulated under different types of regulatory authorities, and frequently by 294 
different FDA Centers, they raise challenging regulatory, policy, and review management 295 
challenges. Differences in regulatory pathways for each component can impact the regulatory 296 
processes for all aspects of product development and management, including preclinical testing, 297 
clinical investigation, marketing applications, manufacturing and quality control, adverse event 298 
reporting, promotion and advertising, and post-approval modifications [50]. 299 
 300 
Biological evaluation of polymeric medical devices that come into direct or indirect contact with 301 
the human body are covered by ISO-10993, “Biological Evaluation of Medical Devices Part 1: 302 
Evaluation 132 and Testing” [51]. The general principles of this ISO-10993 guidance also apply 303 
to combination products, such as drug-releasing VRs, although additional or modified testing 304 
may be required. According to the standard, VRs are classified as devices that contact the 305 
mucosal tissue, and for which a series of initial tests are mandated to evaluate biological effect. 306 
These can include tests of cytotoxicity, sensitization, vaginal irritation, systemic toxicity, 307 
subchronic toxicity, genotoxicity, and implantation, depending on the duration of mucosal 308 
contact. A supplementary evaluation test for chronic toxicity is also required for drug-releasing 309 
VRs that are used for greater than 30-day duration. 310 
 311 
To date, all marketed VRs and most prototype microbicide-releasing VRs are fabricated either by 312 
high-temperature reaction injection molding of medical grade silicone elastomers (Estring®, 313 
Femring®, Progering®, Fertiring®) or high-temperature extrusion of EVA (Nuvaring®). For 314 
example, The International Partnership for Microbicide’s (IPM) DPV VR 004 is manufactured 315 
from Nusil’s MED-4870 silicone elastomer. Certain grades of these polymeric materials meet the 316 
standards of United States Pharmacopeia (USP) Class VI materials (the most stringent of the six 317 
classes of plastic designation). In order to be compliant with USP Class V.e approval, test 318 
materials must pass the ‘Systemic Injection Test’ and the ‘Intracutaneous Test’. Here, extracts of 319 
the test material in saline, alcohol in saline, polyethylene glycol (PEG 400), and vegetable oil, are 320 
injected into mice and rabbits and the animals’ response to the sample extracts compared with a 321 
blank test. USP Class VI materials must pass both the USP Class V.e test plus an implantation 322 
test in which strips of the test material and a negative control are implanted in rabbits for a period 323 
of not less than 120 hr. Hemorrhage, necrosis, discolorations, and infections are macroscopically 324 
observed and degree of encapsulation is scored and compared with a negative control to 325 
determine test passage. Although USP Class VI testing is widely used and accepted in the 326 
medical products industry, some view it as the minimum requirement a raw material must meet to 327 
be considered for use in healthcare applications. USP Class VI testing does not fully meet any 328 
category of ISO 10993-1 testing guidelines currently used by the US FDA (General 329 
Program/Bluebook Memorandum G95-1) for medical device approval. 330 
 331 
2.3.1 Silicone elastomers 332 
Silicone elastomers for use in medical and pharmaceutical applications are prepared through the 333 
chemical crosslinking of functionalised, linear, polydimethlysiloxane molecules. The most 334 
important chemical crosslinking mechanisms involve condensation-cure and addition-cure 335 
chemistries. Condensation-cure systems involve reaction between hydroxy-terminated 336 
polydimethylsiloxanes and a tetraalkoxysilane, resulting in the formation of the cured elastomer 337 
and an alcohol by-product (Figure 3) [52–54]. Although the chemistry of this SE crosslinking 338 
reaction is generally compatible with a very wide range of chemical functional groups, the 339 
alcohol produced can be problematic when an incorporated drug(s) is highly soluble in the 340 
alcohol [55,56]. Crosslinking of addition-cure SE systems relies on the platinum-catalysed 341 
hydrosilylation reaction between hydride- and vinyl-functionalised polydimethylsiloxanes 342 
(Figure 4). Usefully, no by-product is formed with this reaction. However, the platinum (Pt) 343 
catalyst is particularly sensitive to poisoning by certain chemical functional groups, most notably 344 
organotin, organosulfur and certain amine containing compounds. Medical grade silicone 345 
elastomers used in the fabrication of VRs are supplied as either restricted (limited to external use 346 
or short term implant applications ≤ 29 days) or unrestricted grades (for any application, 347 
including long term implantation > 29 days). In general, they are supplied as two-part systems 348 
that need to be intimately mixed to initiate cure. Each part includes the silicone base material – a 349 
complex mixture of silicone polymers and a reinforcing filler (Table 1) – in addition to platinum 350 
catalyst, hydride crosslinker and cure inhibitor components (Table 2).  351 
 352 
2.3.2 EVAs 353 
EVAs are copolymers of ethylene and vinyl acetate that have a long history of use in drug 354 
delivery applications (Figure 5A). The vinyl acetate content (typically ranging from 355 
approximately 10–40%) and the molecular weight characteristics of the EVA material play a 356 
major role in determining the mechanical properties, the ease of processing, and the drug release 357 
rates of the finished drug delivery device. The first controlled release drug delivery systems to be 358 
commercialized – Alza's Ocusert® (an ophthalmic insert releasing pilocarpine at a constant rate 359 
for treatment of glaucoma) and Progestasert® (an intrauterine implant providing constant rate of 360 
progesterone delivery) – were fabricated from EVA. More recently, Implanon®/Nexplanon® (a 361 
long-acting subdermal contraceptive implant releasing etonogestrel), Virtasert® (a ganciclovir eye 362 
implant for treating cytomegalovirus infection) and Nuvaring® (a combination contraceptive VR) 363 
are all fabricated from EVA. Despite the success of Nuvaring®, there have been only a small 364 
number of reports describing use of EVA for microbicide-releasing VRs. The reasons for this are 365 
unclear, although supply of medical grade EVA materials is often more constrained than for 366 
silicone elastomers (due to limited number of vendors). However, EVA polymers may offer 367 
certain advantages over silicone elastomer materials, including lower cost, a wider range of 368 
physicohemical and drug permeation properties due to variation in the vinyl acetate ratio, and the 369 
potential to produce devices with very thin (less than 100 μm) rate controlling membranes using 370 
extrusion processes [57,58]. The experimental NNRTI UC781 showed similar in vivo release 371 
rates and kinetics in rabbits following vaginal administration of ring segments fabricated from 372 
EVA, polyurethane and silicone elastomer [59]. A combination EVA matrix-type ring providing 373 
simultaneous release of the microbicide candidate UC781 and the contraceptive progestin 374 
levonorgestrel (LNG) has also been reported [40]. The Population Council are developing an 375 
EVA core-matrix ring for simultaneous delivery of Medivir-150 (MIV-150), carrageenan (CG), 376 
zinc acetate (ZA) and levonorgestrel (LNG) [60]. 377 
 378 
2.3.3 Polyurethanes  379 
Alternative biocompatible thermoplastic materials, most notably thermoplastic polyurethanes 380 
(TPUs) [42,59,61–64], are also being evaluated for fabrication of microbicide-releasing rings, in 381 
order to extend material choice beyond the relatively hydrophobic silicone elastomers and EVA 382 
polymers. TPUs are multi-phase block copolymers formed by a step-growth polymerization 383 
reaction between diisocyanates, a low molecular weight diol and a high molecular weight diol 384 
(Figure 5B). The low molecular weight diol and the diisocyanate combine to form hard segments 385 
which contribute to the toughness and physical performance properties; the high molecular 386 
weight diol and the diisocyanate combine to form soft segments (responsible for the flexibility 387 
and elastomeric character). The TPU polymerization reaction combines the soft segments and 388 
hard segments into a linear backbone, giving a copolymer with bi-phasic properties. The hard and 389 
soft phases separate as a result of the strong hydrogen bonding between urethane units and/or the 390 
hard segment crystallization. By controlling the ratio of hard to soft segments, TPUs offer a wide 391 
range of physicochemical and drug release properties useful in developing VR formulations 392 
optimized for different types of drug actives. For example, TPUs are available in both 393 
hydrophobic and hydrophilic grades, and both have been reported in the literature for VR 394 
fabrication. CONRAD’s dual-segment, multipurpose prevention technology VR releasing TFV 395 
and LNG is fabricated from two different polyurethane materials (Lubrizol’s Tecoflex™ and 396 
Tecophilic™ polymers; GMP versions are sold under the Pathway™ brand), one for each 397 
segment and selected to optimize permeation of the actives [61]. TPU VRs are generally 398 
fabricated by blending/compounding the drug with the polymer followed by hot-melt extrusion 399 
processes (although injection molding is also possible). Depending upon the properties of the 400 
drug in the polymer, the drug may associate mostly with the soft segments or with both the soft 401 
and hard segments.  402 
 403 
2.3.4 Other materials 404 
Microbicide-release vaginal rings fabricated from hydrogel materials have been reported [65–67]. 405 
Han et al. described rings composed of biosoluble acacia gum or nonbiodegradable hydrogel of 406 
2-hydroxyethyl methacrylate (HEMA) and sodium methacrylate (SMA) [P(HEMA- co-SMA)] 407 
for the in vitro release of AZT and various non-hormonal contraceptives [65]. In a follow-up 408 
paper, the same technology was extended to release of dapivirine (TMC120), PMPA and Boc-409 
lysinated betulonic acid (Boc-LBA)] [66]. For each drug, in vitro release was maintained for no 410 
less than 15 and 28 days from the acacia gum and 2-hydroxyethyl methacrylate and sodium 411 
methacrylate rings, respectively, at concentrations higher than the minimum effective dose for 412 
HIV inhibition. The same group of researchers have more recently reported a biocompatible VR 413 
composed of a nanoporous poly(diol citrate) elastomer hydrogel for the delivery of non-hormonal 414 
contraceptives and anti-HIV agents [67]. Following synthesis of the prepolymer (by mixing and 415 
heating a mixture of 1,8-octanediol and citric acid) and subsequent mixing/processing with the 416 
active agents, the viscous polymer mixture was poured into a ring mold and heated at 80 °C for 4 417 
days to form the final ring device. Use of organic solvents and a complex and protracted 418 
manufacturing method are likely to restrict the scope and practicality of this VR technology.    419 
 420 
Biodegradable polycaprolactones (PCLs) are commonly used for production of biomedical 421 
implants and drug delivery devices in the form of films, micro- and nanoparticles. Pertinent to 422 
this review, microporous PCL vaginal insets offering 30-day controlled release of TFV have 423 
recently been reported [68]. Unlike more conventional polymer materials used to construct ring 424 
devices, preparation of these prototype rings involves dissolving/dispersing the polymer/drug in 425 
acetone followed by a methanol extraction process, resulting in a relatively flexible porous insert. 426 
Such a solvent method is not safe, practical or scalable for commercial ring manufacture. 427 
However, PCL is amenable to hot-melt injection molding and extrusion. The porous nature of 428 
these materials, which facilitates fluid uptake, offers an alternative mechanism of release for 429 
those microbicidal drugs that are not amenable to permeation control polymer systems.   430 
 431 
2.4. Mechanisms of microbicide release from vaginal rings  432 
All of the VR products currently marketed (Estring®, Femring®, Nuvaring®, Fertiring® and 433 
Progering®) and the DPV Ring-004 in Phase III clinical testing rely on release of the active from 434 
the device via a permeation-controlled mechanism [20]. This permeation process can be 435 
considered as three discrete and consecutive steps – drug solvation in the surrounding polymer, 436 
molecular diffusion of the solvated drug molecules within the polymer, and partition of the drug 437 
from the surface of the ring into the surrounding release medium [25]. The driving force behind 438 
the permeation mechanism of drug release from VRs is passive diffusion down concentration 439 
gradients that exist from within the device to the fluid in the vaginal vault. The nature of the 440 
release profile observed in vitro depends upon the ring design and allows differentiation of ring 441 
type based on characteristic release profiles e.g. matrix and reservoir-type rings. Recently other 442 
mechanisms of drug release beyond permeation control have been investigated including 443 
combination swelling and permeation controlled systems, pod-insert type systems and 444 
osmotically controlled systems. 445 
 446 
2.4.1 Drug release from matrix-type rings 447 
In the simplest matrix-type ring design, drug is homogeneously dispersed throughout the entire 448 
ring body (Figure 2B). For most drug compounds, solubility in the polymer is lower than the 449 
amount of drug present, such that drug is present in both the solvated and solid (usualy 450 
crystalline) states. Upon placement of the ring into a release medium, solvated and solid drug 451 
initially present at the outer surface of the ring will diffuse/dissolve into the surrounding fluid, 452 
giving rise to the so-called ‘burst effect’ [25,55]. Once this very outermost layer of drug has ben 453 
released, other solvated drug molecules from within the bulk of the VR will diffuse to the ring 454 
surface and partition into the surrounding fluid. The solubility sites within the polymer that have 455 
been depleted due to drug release are then replenished by dissolving of further drug molecules 456 
from the solid drug particles dispersed within the matrix. As a result of these processes, a series 457 
of equilibria are established – solid drug in polymer ⇋ dissolved drug in polymer ⇋ drug in 458 
release medium / vaginal fluid – which are maintained so long as excess solid drug is present 459 
within the device. Given sufficient release time, an advancing drug-depletion zone forms with 460 
matrix-type VRs [69]. 461 
 462 
Usually, the rate-limiting step in release of drugs from matrix-type VRs is molecular diffusion of 463 
the drug through the polymer, which, under sink condition, is commonly modelled by the 464 
Higuchi equation [70,71]. Given that the Higuchi model was originally derived for planar 465 
matrices rather than a torus-shaped system [72], Helbling et al. present an alternative and more 466 
accurate mathematical model for controlled release of drugs from torus-shaped matrix-type 467 
devices [72]. Representative daily and cumulative release profiles for matrix-type VRs are 468 
presented in Figure 6. There is characteristic reduction in the daily release as the depletion zone 469 
boundary recedes into the ring thereby increasing the diffusional path of dissolved drug to the 470 
surface of the ring. The release rate is dependent upon the drug solubility in the polymer, the 471 
diffusion coefficient of the drug in the polymeric material of the ring, the drug loading and the 472 
ring surface area.  473 
 474 
Through judicious choice of release medium, matrix-type rings can give rise to both diffusion-475 
controlled and partition-controlled release mechanisms [73]. Diffusion-controlled release 476 
predominates when the drug solubility in the release medium is sufficiently high [74]. In this 477 
scenario, the shape of the release profile is relatively insensitive to the partition coefficient and 478 
solubility of the drug considered. However, as the solubility of the drug in the release medium 479 
falls the mechanism of release will shift to a partition-controlled one [74]. Here the cumulative 480 
drug release profile is linear with time, corresponding to zero-order release. This can be thought 481 
of as having a constant supply of dissolved drug in the polymer waiting to be released into the 482 
surrounding fluid with the rate-limiting step being the partitioning of the drug into vaginal 483 
fluid/release medium rather than diffusion through the polymer matrix. The drug release process 484 
is then a function of the partition coefficient of the drug between the polymer and the fluid 485 
surrounding the ring.  486 
 487 
The 25 mg DPV Ring-004 – the most advanced microbicide ring, currently in Phase III clinical 488 
trials – has a matrix design [75,76]. Other examples include the EVA rings containing either 489 
MIV-150 [77] or MIV-160 developed by the Population Council [78], both of which exhibit 490 
partition-controlled release into an acetate buffer with surfactant system and the hot melt 491 
extruded polyether urethane ring containing UC781 [79]. Combination matrix-type rings 492 
containing more than one microbicide have also been investigated [80,81]. 493 
 494 
2.4.2 Drug release from reservoir-type rings 495 
In simplest form, reservoir-type VR designs comprise a central drug-loaded polymer core (again, 496 
drug is generally present in both the dissolved and solid state) surrounded by a non-medicated 497 
polymeric rate-controlling membrane (Figure 2E–G). For example, each of the marketed VRs 498 
Nuvaring®, Estring® and Femring® is a reservoir design, although the length of the drug-loaded 499 
core varies between the devices. Most commonly, release is governed by a permeation 500 
mechanism involving dissolution and diffusion of drug molecules in the polymer materials from 501 
which the ring is fabricated. Drug release rates from reservoir VRs are typically constant with 502 
time, consistent with zero-order kinetics. Sometimes, depending on the drug/polymer 503 
combination, the manufacturing conditions and the stability conditions, a lag or burst effect can 504 
be observed during the intial release period (Figure 6). As only dissolved drug can migrate 505 
through the ring structure from the core to the periphery, the rate of release is controlled by the 506 
fixed thickness of the membrane layer. Constant rate of drug release will continue until the solid 507 
drug within the core becomes depleted. A fixed diffusional path length gives rise to a fixed 508 
release rate dependent upon the rate of partitioning into the surrounding fluid and the size of the 509 
sheath layer. Drug release kinetics in this case are controlled by the thickness of the rate-510 
controlling membrane and the relative partition coefficient of the drug between the polymer and 511 
the release medium [82]. Owing to their design, reservoir-type devices offer lower release rates 512 
compared with matrix-type rings. Examples of reservoir-type microbicide VRs include the 90-513 
day TFV ring [83], the tenofovir disoproxil fumarate (TDF) reservoir ring [63,84] and the DPV 514 
reservoir rings tested by IPM [56,85]. 515 
 516 
2.4.3 Drug release from pod insert type rings 517 
Pod insert VRs comprise compacted drug powder inserts coated with a semipermeable polymer 518 
and embedded in a polymeric (often silicone elastomer) VR body [86–89]. This design offers 519 
pseudo zero-order release profiles and can be used to deliver a broad range of compounds 520 
including hydrophilic and macromolecular actives. Drug release, which occurs by permeation 521 
through a delivery window in the ring body, can be readily altered by changing the window 522 
diameter, altering the amount and composition of the core polymer coating, or by increasing or 523 
decreasing the number of pods per ring [86]. The pod ring has been investigated for the delivery 524 
of the hydrophilic drugs TFV and ACV [89,90], and simultaneius delivery of five different drugs 525 
– TFV, nevirapine (NVP), saquinavir (SQV) and the hormonal contraceptive combination 526 
etonogestrel (ETN) and ethinyl estradiol (EE) [91]. The release of antibodies has also been 527 
investigated (see Section 3.1) [92]. 528 
 529 
2.4.4 Combination swelling and permeation controlled release systems 530 
TPUs have been used in the manufacture of various ring types, including matrix [42,44,79], 531 
reservoir [44,63] and segmented designs [43,61] (Figure 2). Segmented polyurethane rings, 532 
comprising a water swellable polyurethane segment and non-water swellable polyurethane 533 
segment within the same ring device, are useful for release of compounds with very different 534 
hydrophilicities. For example, a segmented ring has been reported for simultaneous delivery of 535 
TFV and DPV [43]. Depending upon microbicide solubility in the release media, the release 536 
mechanism can be diffusion controlled or partition controlled [42,79]. The use of a water 537 
swellable polymer requires that polymer swelling be taken into account for the release 538 
mechanism [44]. Variations on the segmented ring design have also been described, including the 539 
use of hollow tube like cores with osmotically active excipients present to encourage water 540 
ingress and drug release [83] and segmented dual reservoir-type designs (Figure 2G) [61]. A 541 
dual-segment version of this latter ring type has been developed as an MPT device offering 542 
release of TFV from one segment and LNG from the other [61]. 543 
 544 
2.4.5 Osmotically controlled release systems 545 
A new core-matrix MPT ring containing four different APIs has recently been reported by the 546 
Population Council (Figure 2J) [60]. This VR comprises a compressed core containing the solid 547 
hydrophilic agents ZA (targeting HIV-1 and HSV- 2) and CG (targeting HPV and HSV-2). The 548 
core is embedded within a hot-melt extruded EVA ring body containing the hydrophobic 549 
antiretroviral MIV-150 and the hydrophobic progestin LNG. Pores drilled in the EVA ring allow 550 
fluid ingress to dissolve and release the ZA+CG from within the core. In this manner, different 551 
mechanisms control release of the various actives. The concept of using rings to hold inserts 552 
containing highly hydrophilic excipients to promote release of macromolecular drugs has also 553 
previously been reported [93]. Recently, a device utilizing polymer swelling for the controlled 554 
release of macromolecules has been reported [94].  555 
 556 
2.5. Manufacturing approaches 557 
VR manufacturing techniques are dependent on the design, APIs, materials and production 558 
volume requirements of the device. For most microbicide-releasing VRs, the polymeric 559 
excipients used in their manufacture play a major role in controlling the release of drug(s), 560 
usually by limiting the rate of drug diffusion through the matrix body or a non-medicated layer. 561 
Thermosetting and thermoplastic polymers are the most commonly used materials used in the 562 
manufacture of microbicide-releasing VRs; thermosetting polymers cure irreversibly, while 563 
thermoplastic polymers can be thermally cycled. Summaries of the manufacturing approaches 564 
used for the different material categories are found in Figures 7 and 8. 565 
 566 
2.5.1. Thermosetting materials 567 
Silicone elastomers are the main thermosetting polymer used in the manufacture of VRs. They 568 
are available in a variety of curing chemistries including condensation-cure (Figure 3), addition-569 
cure (Figure 4), room-temperature vulcanizing (RTV) and ultra-violet (UV). The chemistries of 570 
condensation-cure and addition cure systems are described in Section 2.3.1.  571 
 572 
The basic manufacturing principles for condensation-cure silicone elastomer rings are the 573 
homogenous distribution of n-propylorthosilicate into a silicone elastomer base followed by 574 
addition of the active ingredient and thorough mixing (Figure 7). A tin catalyst is dispersed into 575 
the formulation and final forming operations are performed at temperatures typically above 576 
100°C.  577 
 578 
For drug molecules with non-reactive functional groups, addition-cure systems are the preferred 579 
option. Addition-cure silicone elastomers are two component systems (Part A and Part B) which 580 
are typically combined in a 1:1 ratio [20,38,56,69,80,95–97]. Active ingredients are usually 581 
dispersed in equal amounts into each elastomer component in separate batch mixing operations, 582 
and then these active mixtures are combined in appropriate ratios using an additional mixing 583 
operation before final forming, heating and curing of the ring. 584 
 585 
At a laboratory scale, mixing of components and API into the elastomer base has been performed 586 
by hand, overhead paddle, planetary [80] and double-asymmetric centrifugal (DAC) mixing 587 
[80,96]. The selection of a suitable mixing method depends on the viscosity of the silicone 588 
component, the amount of excipients and/or API being added, the sensitivity of the components 589 
to processing conditions, batch size requirements and also the degree of scalability necessary for 590 
a given stage of product development. DAC mixing is capable of dispersing multiple APIs in 591 
silicone elastomer materials to allow the production of combination microbicide matrix-type VR 592 
formulations [80,81,96]. 593 
 594 
Given the relatively rapid kinetics of the crosslinking reaction for both condensation and addition 595 
cured silicone elastomer systems, final downstream mixing is ideally performed immediately 596 
before the product forming operation occurs. Working with small batches of premixed material 597 
can mitigate the problem of the elastomer curing prior to completion of final product forming but 598 
accepted best practice is the use of static mixing equipment to combine the incoming streams of 599 
components; just subsequent to forming. This contrast is highlighted again by Fetherston et al. 600 
[80] in their different approaches to producing R&D scale batches using a DAC mixer working 601 
with mixed batches of Part A and Part B API loaded elastomer compared to the method used 602 
during large scale manufacturing runs for stability trial samples where the two separately pumped 603 
A and B streams were combined using a static mixer, prior to being fed into an injection molding 604 
machine. 605 
 606 
Silicone elastomer VRs are usually fabricated using injection molding processes. After final 607 
combination of all liquid components, material is transferred into an injection vessel that 608 
pressurizes and provides a mechanism of control over the ‘shot’, specifically the volume of 609 
material that flows into a mold tool containing a negative ring cavity. The mold tool is 610 
temperature controlled and heated to a set point that provides crosslinking of the silicone 611 
elastomer in the ring as rapidly as possible without causing detrimental effects to the initial 612 
injection – linked to ring quality, or degradation of API contained therein. The processing 613 
parameters that can be controlled during injection molding operations of liquid silicone 614 
elastomers and their potential effect on product quality have not been widely reported. Evidence 615 
from studies of Pt-catalysed silicone elastomer maxillofacial prostheses suggest that that low 616 
temperature-long duration vs high temperature-short duration curing conditions produce no 617 
appreciable differences in material hardness but mold material could have an effect [98]. 618 
 619 
For silicone elastomer reservoir-type VRs, the drug-loaded core component is formed as for a 620 
matrix-type ring. This core is then placed into a mold that allows half of the core cross-sectional 621 
diameter to be covered in a non-medicated membrane of chemically-compatible silicone 622 
elastomer.  When cured, the half-sheathed ring is removed and placed into a third mold assembly 623 
that allows the final part of the sheath layer to overmolded around the core, forming a full rate 624 
controlling membrane around the API loaded core [20]. There is increased complexity in the 625 
manufacture of silicone reservoir rings compared to their matrix counterparts due to the 626 
importance of centrally locating the core within the membrane to ensure consistent drug release 627 
rates are obtained. In addition a two or three step injection molding process is required that has 628 
implications for manufacturing costs. 629 
 630 
Reservoir-type microbicide rings can also be manufactured by injection molding to contain 631 
partial-length cores (unpublished). Here, full cores are molded and the required segment size is 632 
cut from the full core, e.g. half, quarter etc. The overmolding process is then performed in the 633 
same manner as for full core, injection molded reservoir rings. A non-microbicide example of a 634 
silicone multi-core reservoir VR containing oxybutynin examined different fractional segment 635 
cores, using this approach to reduce the day one ‘burst effect’ observed in full-length cores [55]. 636 
 637 
An additional forming operation for silicone elastomer products is the extrusion of rod 638 
geometries. This approach is particularly useful when working with high drug loadings (> 40% 639 
w/w) in silicone elastomer systems, where viscosity of the silicone mixes exceed the capability of 640 
the injection molding process. For silicone elastomer extrusion, drug-loaded material is conveyed 641 
using an Archimedean screw inside a temperature-controlled barrel. A circular die placed at the 642 
output from the extruder forms a rod of defined diameter and this is passed through a line of 643 
convection ovens or a static oven to cure the elastomer. One example of the use of API-loaded 644 
silicone rods is the Population Council’s nestorone (NES) / EE ring [99] that has two separate rod 645 
inserted into a single ring device. Once active silicone rods have been extruded, they are cut to 646 
length and either overmolded with a compatible silicone or, as in the case of the NES/EE ring, 647 
inserted into a separately produced, non-medicated silicone ring body. Whilst this example is for 648 
a contraceptive ring application, the manufacturing techniques could equally apply for 649 
microbicide releasing VRs delivering two or more actives. 650 
 651 
A subset of reservoir-type silicone VRs exists where the ring body acts as a non-medicated 652 
holder for active silicone cores. Examples include the Population Council’s NES/EE VR, where 653 
the ring body is manufactured separately and the cores are added in a separate operation [99], and 654 
a tablet insert ring in which API-loaded capsules are inserted into an injection molded ring body 655 
manufactured using mold tooling that forms defined hole diameters traversing the cross section 656 
of the ring [93,100]. One advantage of this manufacturing approach is that thermally-sensitive 657 
actives, such as proteins or peptides, can be readily incorporated into ring devices without 658 
exposure to the elevated temperatures required to cure the silicone elastomers. A different type of 659 
pod ring has been developed using cropped, spherical pods of solid API coated with permeable 660 
and semi-permeable polymers. Early prototypes of the device were manufactured with a recess 661 
for pod insertion that was backfilled with silicone [86]. Delivery channels were mechanically 662 
punched through the base of the ring body. The pods were manufactured separately giving the 663 
capacity to deliver multiple API [91]. In recent advances to the manufacturing process, the 664 
delivery channels were molded directly into the silicone sheath layer [101]. First, a ring body is 665 
injection molded with a recess for each pod that includes a cylindrical orifice or ‘delivery 666 
channel’ at the base, formed during the molding process - designed to control release rate of the 667 
individual API loaded pods. The pods are inserted into their recess and fresh silicone is used to 668 
backfill the recess, locking the pods in position and completing the ring profile. 669 
 670 
2.5.2 Thermoplastic rings 671 
Thermoplastic rings differ from thermosetting VRs in their manufacturing approach, specifically 672 
in the steps required to create homogenous dispersions of API in the viscous thermoplastic melts. 673 
For matrix-type VRs, the API is first dispersed in the selected matrix polymer (powder or pellet 674 
form) before final forming operations occur (Figure 8). The types of equipment used to disperse 675 
API throughout the base polymer are Banbury type mixers and single/twin screw compounders 676 
suitable for melting the polymer and high shear/torque mixing. Another method used to disperse 677 
API into polymer prior to extrusion is solvent casting [42,43] with drug and polymer dissolved in 678 
suitable solvent then evaporated to form films that are subsequently chopped up and fed into the 679 
extruder. Extruders have the capability to provide a continuous output of API loaded rod, sized 680 
according to a mold or ‘die’ fitted to the output of the extrusion barrel. This rod can be used 681 
directly to create rings if it is cut, shaped into a torus and butt welded to form seam joint [42]. 682 
Also, with the advantage of simple thermo-mechanical jointing methods, it has been possible to 683 
combine segments of compatible API matrix rods to form segmented matrix rings containing 684 
multiple API [43]. Alternatively, as for DPV loaded EVA matrix rings, the rod can be cut into 685 
granules via pelletization and used in injection molding operations to form the final ring. 686 
Injection molded thermoplastic matrix rings have also been adopted for combinations of API for 687 
HIV and contraceptive function [40]. 688 
 689 
Co-extrusion is a widely-adopted method for manufacture thermoplastic reservoir VRs. Here, 690 
API is compounded in an extruder to provide a homogenous output of API+polymer, while an 691 
additional extruder provides a secondary stream of non-medicated polymer that is compatible 692 
with the polymer used in the active stream. The API loaded stream forms a rod that is coated with 693 
the non-medicated stream forming a core/sheath configuration with core diameter and sheath 694 
thickness dictated by the geometry of the die. The rod is cut into defined lengths, placed into a jig 695 
that bends it into a toroid and butt-welded to form a seam. A non-microbicide exemple of a 696 
commercial thermoplastic reservoir ring manufacture is Nuvaring [58,102]. Powdered EVA is 697 
mixed with the contraceptive hormones using a twin screw extruder and fed through a co-698 
extrusion die, while a second extruder feeds non-medicated EVA to provide a rate controlling 699 
sheath layer thickness of approximately 100 microns.  700 
 701 
Reservoir-type VR design principles have also been used to create microbicide loaded 702 
thermoplastic devices using polyurethane sheathes [83]. Hydrophilic polyurethane was extruded 703 
into a hollow tube configuration and the lumen filled with microbicide powder only or powder 704 
and glycerol/water combinations, end sealed using an induction weld. This straight piece of 705 
sealed tubing was then shaped in a ring die, annealed then the two ends of the ring were joined 706 
using a final induction weld. Different formulations of a combination microbicide/contraceptive 707 
hormone VR were fabricated from conventionally co-extruded LNG reservoir strands and hollow 708 
core design TFV strands [61]. To reduce leakage of LNG into the TFV reservoir strand, low 709 
permeability polymer caps were placed between the different reservoir segments, and all of the 710 
various joints were induction welded. 711 
 712 
The Population Council has recently reported a multipurpose prevention ring containing API to 713 
prevent HIV, HSV, HPV in combination with a contraceptive hormone [60]. The device is a 714 
combination of matrix and core technologies in order to release both hydrophobic and 715 
hydrophilic actives.  The outer body of the ring was formed in two halves using separate hot melt 716 
extrusion stages combining EVA, microbicide and contraceptive hormone. The first extrusion 717 
stage produced a semi-circular; half ring with a channel into which an inner core formulation 718 
using hydrophilic actives was formed. The second hot melt extrusion step produced the upper 719 
half of the matrix ring minus the channel and completed the ring profile. Orifices of defined 720 
diameter were drilled through the matrix outer body to facilitate release of the hydrophilic core. 721 
 722 
2.6. Microbicide candidates 723 
It is not the remit of this article to provide a comprehensive review of the dozens of HIV 724 
microbicide candidates that have been evaluated over the years. Instead, the focus here is on 725 
those molecules that either have previously been tested or are being actively developed in VR 726 
formulations. A short overview of non-specific microbicides is presented first, before a more 727 
comprehensive review of ARV-based microbicides, and particularly the lead candidate ARVs 728 
DPV and TFV.   729 
 730 
2.6.1. Non-antiretroviral microbicides 731 
First generation microbicide candidates tended to be non-antiretroviral compounds that had 732 
broad-spectrum activity against HIV and other sexually transmitted infections (STIs) (Table 3). 733 
These non-specific microbicides covered several modes of action, often not specific to the HIV 734 
life cycle and including surface active detergents and surfactants that could destroy or disrupt the 735 
viral membrane, pH acidifiers that could maintain the protective pH of the vagina and long chain 736 
polyanionic compounds that could non-specifically inhibit viral fusion, attachment and entry into 737 
the host cells [103–107].  738 
 739 
Although the majority of broad-spectrum microbicide candidates (e.g. Savvy, BufferGel, 740 
cellulose sulfate) were formulated in vaginal gels and creams, several VR formulations have also 741 
been evaluated (Table 3). In 2003, a silicone elaastomer matrix-type VR releasing nonoxynol-9 742 
was reported [18]. Although N-9 had shown promising antiviral activity against HIV-1 and other 743 
sexually transmitted infections in vitro [107–109], development of N9 microbicide products was 744 
halted following the discovery that it failed to provide protection against HIV-1 during clinical 745 
trials and that repeated exposure to the spermicidal compound actually damaged the vaginal 746 
epithelium and increased the risk of HIV-1 acquisition [19,110–112]. ZA has shown early 747 
promise as a broad-spectrum microbicide against HIV-1 and herpes simplex virus 2 (HSV-2) 748 
[113–115], despite an unknown mechanism of action.  749 
 750 
Another non-specific microbicide being developed as a ring formulation is Boc-LBA, a betulonic 751 
acid derivative with anti-HIV activity in vitro [66]. This multi-step entry and fusion inhibitor was 752 
first formulated in a bio-soluble acacia gum reservoir-type VR (Table 3) [26,66]. More recently a 753 
nanoporous hydrophilic hydrogel-based combination ring product (BioringsTM) containing Boc-754 
LBA in combination with ferrous gluconate (a non-hormonal contraceptive), ascorbic acid, 755 
polyamino-polycarboxlic acid mixtures and the nucleotide reverse transcriptase inhibitor (NRTI) 756 
TFV is undergoing early preclinical development by BioRing LLC [67]. 757 
 758 
Griffithsin (GRFT), a naturally occurring lectin found in red algae (Griffithsia sp.) is also 759 
undergoing early preclinical evaluation in a VR device. GRFT has shown potent, broad-spectrum 760 
antiviral activity as a non-specific entry inhibitor against HIV-1, HIV-2 and other STIs including 761 
HSV-2 in vitro warranting further investigation as a topical microbicide [116–119]. Studies have 762 
shown that GRFT, a carbohydrate binding agent, binds to mannose rich glycans on viral envelope 763 
glycoproteins of HIV and HSV-2, coating the virus surface and thereby preventing/inhibiting 764 
penetration of host cells [117,120].  765 
  766 
The high profile clinical failures of many non-ARV microbicides [121–123] has directed the 767 
microbicide field, and VR development specifically, towards use of potent ARVs that act 768 
specifically against the HIV life cycle. However, concerns over the development of ARV 769 
resistant strains mean that there may still be a place for non-specific, broad-spectrum 770 
microbicidal agents that are safe and effective against HIV and a range of sexually transmitted 771 
infections. 772 
 773 
2.6.2. Antiretroviral microbicides 774 
A large number of both approved and experimental ARV drugs have been evaluated for 775 
formulation in VR devices (Table 4). The two lead candidate microbicides – TFV and DPV – are 776 
now discussed in detail.  777 
 778 
Tenofovir (({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid, also 779 
known as PMPA, Table 4) and its oral prodrug form TDF (marketed as Viread, Table 4) are 780 
nucleotide analogue antiviral drugs made by Gilead Sciences Inc. and commonly used in the 781 
treatment of HIV infection. Consistent with other hydrophilic, negatively charged, acyclic 782 
phosphonate nucleotide analogues, TFV suffers poor oral bioavailability. TDF, however, in 783 
which the negative charges of its phosphonic acid groups are masked by phosphodiester 784 
modification, is significantly more lipophilic resulting in greatly enhanced oral bioavailability 785 
[124–127]. Following absorption, TDF rapidly undergoes esterase hydrolysis to TFV, which is 786 
then metabolized intracellularly to its active anabolite tenofovir diphosphate, a competitive 787 
inhibitor of HIV-1 reverse transcriptase that interferes with and terminates DNA replication.  788 
 789 
In 2006, Gilead Sciences granted a co-exclusive, royalty-free license to CONRAD and the IPM 790 
to develop TFV vaginal formulations for use by women in developing countries to prevent HIV 791 
infection. Since then, a large number of journal papers have been published describing either 792 
TFV or TDF formulated for vaginal application, including gels [128–144], tablets [145–147], 793 
nanoparticles [148–150] and VRs [43,61–63,68,83,86–89,91,151,152].  794 
     795 
The hydrophilic nature of both TFV and TDF results in poor release characteristics from 796 
traditional permeation-controlled VR formulations fabricated from silicone elastomer or EVA, a 797 
consequence of the limited solubility of the TFV and TDF in these polymeric materials. 798 
Therefore, many of the VR strategies pursued for these drugs have involved use of novel ring 799 
designs and/or alternative polymer systems that overcome this permeation obstacle. The various 800 
ring types reported for delivery of TFV and TDF are summarized in Table 5. ‘Pod VRs’ comprise 801 
one or more drug-loaded pods embedded within a non-medicated silicone elastomer ring body 802 
containing delivery channels sited adjacent to each pod (Figure 2). The pods themselves are 803 
effectively small, compressed, solid tablets coated with a semi-permeable polymer (such as 804 
polylactic acid) to offer osmotic control [86]. By adjusting the number of pods and the width of 805 
the delivery channels, VRs can be fabricated containing multiple drug compounds with 806 
independent control of release rate. These pod rings have been widely studied for controlled 807 
release of TFV and TDF, either alone [88,89] or in combination with other ARV [91], antiviral 808 
[86,89] and contraceptive drugs [91]. Typically, pod rings offer near constant drug release rates 809 
in vitro and maintain constant levels in the relevant biological compartments (cervicovaginal 810 
fluid, vaginal tissue and blood plasma) during the ring use period. In a 28-day comparative 811 
pharmacokinetic study in sheep, pod rings containing TDF produced drug tissue levels 86-fold 812 
higher than similar ring containing TFV, despite similar concentrations of each drug reported in 813 
cervicovaginal lavage [88]. A similar pharmacokinetic study in pig-tailed macaques demonstrated 814 
that TFV concentrations in vaginal lavage and tissue could be modulated by modification of the 815 
pod ring design by adjusting the size of the TFV reservoir and/or the width of the delivery 816 
channel [87]. The ability of the pod VR design to simultaneously deliver multiple drug 817 
compounds makes it an interesting platform for development of a multipurpose technology 818 
(MPT) VR, as exemplified by a pharmacokinetic study in sheep demonstrating steady state 819 
release of five – TFV, NVP, SQV, ETN and E2 – from a single pod-type ring device [91].  820 
 821 
An alternative approach that has been used successfully to provide sustained vaginal delivery of 822 
TFV or TDF involves VR devices manufactured, at least in part, using hydrophilic thermoplastic 823 
polyurethanes (TPUs). The ability of these polymers to swell in the presence of aqueous liquids 824 
(including in vitro release media and presumably vaginal fluid) offers an alternative release 825 
mechanism to the permeation control offered by rings fabricated from hydrophobic silicone 826 
elastomer and EVA materials. Equilibrium water absorption values for TPUs can range from 20–827 
900% depending on selection of the polymer grade. For VR fabrication, water absorption 828 
capacities at the lower end of the range are used [43,83], since excessive swelling in vivo would 829 
likely be problematic from the perspectives of both ring expansion / mechanical pressure and 830 
vaginal fluid uptake. Rings containing two different matrix-type TPU segments, one hydrophilic 831 
and the other hydrophobic, have been reported for co-delivery of TFV and DPV [43]. As 832 
expected with matrix-type configurations, the amount of drug released from these rings decreased 833 
with time. By incorporating TFV powder or a TFV+glycerol+water mixture into the lumen of 834 
extruded TPU tubing and then joining the ends of the tubing to form a reservoir-type ring device, 835 
zero-order TFV release kinetics were achieved [83]. Release rates were greater for rings 836 
comprising the TFV+glycerol+water mixture, and the TFV release rate increased with 837 
equilibrium swelling value of the hydrophilic TPU. In a sheep PK study, rings fabricated from 838 
the 35% w/w swelling TPU and containing the TFV+glycerol+water mixture provided 839 
maintenance of TFV vaginal fluid concentrations close to 106 ng/g over the 90-day study period 840 
[83]. By comparison, the control 1% w/w TFV gel administered once daily showed TFV vaginal 841 
fluid levels steadily declining from 106 to 104 ng/g over a 28-day period. A similar ring design 842 
containing TDF (rather than TFV) in combination with sodium chloride as an osmotic agent 843 
offered protection against repeated vaginal challenge with simian human immunodeficiency virus 844 
162p3 (SHIV162p3) in pig-tailed macaques over 28 days [63]. TFV levels in vaginal secretions 845 
and tissue remained consistent for 6 months with no adverse safety concerns [152]. 846 
 847 
TFV vaginal gel has previously shown a 39% reduction in HIV and an unanticipated 51% 848 
reduction in HSV-2 acquisition when used by women [13]. This HSV activity has also been 849 
demonstrated in in vitro cell and explant models for a TPU VR containing TDF [62], further 850 
supporting the concept of a MPT ring. TFV, in the form of a glycerol paste, has also been 851 
successfully combined with the contraceptive progestin LNG in a segmented dual-reservoir TPU 852 
VR offering continuous release of both drugs over 90 days [61].    853 
 854 
Dapivirine (DPV), also known as 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-855 
pyrimidinyl]amino]benzonitrile and referred to in the early literature as TMC120, is an 856 
experimental ARV drug that acts against HIV by inhibiting the reverse-transcriptase enzyme. 857 
Like many ARV HIV microbicides, DPV was originally developed – by Janssen Research and 858 
Development (formerly Tibotec Pharmaceuticals Ltd.), a subsidiary of Johnson & Johnson – as 859 
an oral ARV compound for treatment of HIV/AIDS. However, DPV showed such poor oral 860 
bioavailability in early stage clinical studies (due to its extremely low aqueous solubility) that this 861 
treatment option was abandoned. The compound was subsequently repurposed for vaginal 862 
application in 2004 when Tibotec granted IPM a non-exclusive, royalty-free license to develop 863 
DPV as a microbicide for use in low/middle income countries. In 2014, Janssen granted IPM 864 
exclusive worldwide rights to DPV. During this time, DPV has been extensively tested in a wide 865 
range of vaginal formulations, including gels, films, rings, freeze-dried matrices, nanoparticles, 866 
capsules, tablets and rings. IPM has completed numerous Phase I/II clinical trials of the 867 
compound in Africa, Europe and the United States (Table 6), all of which have demonstrated 868 
good safety, tolerance, user acceptability and pharmacokinetic profile. In response to concerns 869 
over poor user adherence to gel products and the preference for a single device offering sustained 870 
vaginal delivery of ARV compounds over extended time periods, IPM have now prioritized 871 
development of their DPV-releasing VR [153].    872 
 873 
Proof-of-concept for a DPV-releasing VR was first demonstrated in in vitro studies that reported 874 
continuous, zero-order release from core-type (also known as reservoir-type, Figure 2), silicone 875 
elastomer, VRs over 71 days [20]. Based on upper limits for the volumes of cervicovaginal fluid 876 
and semen, and assuming in vivo release rate matched in vitro release, the 136 μg/day release rate 877 
was calculated to be capable of maintaining vaginal concentrations of DPV several orders of 878 
magnitude in excess of reported HIV inhibitory concentrations. Subsequent Phase I clinical 879 
studies conducted in Belgium assessed the safety and PK of a matrix-type (25 mg DPV loading) 880 
and two different core-type (25 mg and 200 mg DPV loadings) silicone elastomer VRs [56,85]. 881 
The 25 mg matrix-type ring, in which the solid crystalline drug is dispersed throughout the entire 882 
volume of the device, produced higher concentrations of DPV in vaginal fluid, vaginal tissue and 883 
blood plasma compared with the core-type rings, reflecting the ready availability of drug at the 884 
ring surface. Both the core-type and matrix rings were safe and well tolerated and delivered DPV 885 
to the vaginal region for 28 days at concentrations over 4 logs greater than the EC50 for wild-type 886 
HIV-1 (LAI) in MT4 cells (0.3 ng/mL) [154,155]. Importantly, systemic exposure of DPV with 887 
all ring formulations was deemed sufficiently low to alleviate concerns concerning the emergence 888 
of resistance strains of HIV. 889 
 890 
Early DPV ring prototypes were fabricated using condensation-cure silicone elastomer systems 891 
[20,26,56,85,153]. The curing reaction associated with these materials produces a volatile alcohol 892 
by-product that detrimentally affected DPV distribution within the ring and its release after 893 
storage. As a result, the current version of the DPV-releasing VR, a 28-day matrix-type device 894 
containing 25 mg micronised DPV (Ring-004), is fabricated using an addition-cure silicone 895 
elastomer that produces no cure by-product. Compared with core-type rings (Figure 2), the 896 
simplicity of the matrix design of Ring-004 ensures ease of manufacture, low cost of 897 
manufacture, and higher pharmacokinetic exposure. A recent safety and pharmacokinetic study in 898 
women testing consecutive use of multiple 004 rings for up to 57 days reported detectable DPV 899 
concentrations in vaginal fluid and plasma within 4 hr after ring insertion, indicating rapid release 900 
and absorption of DPV [76].      901 
 902 
With a view to expanding options for testing human-sized VR formulations in animal models, 903 
Holt et al. recently reported safety and pharmacokinetic evaluation of the DPV Ring-004 in 904 
Suffolk cross sheep [156]. DPV plasma and vaginal fluid levels were lower than those measured 905 
in previous ring clinical studies [56,76,85,157]. DPV was also detected remotely in the 906 
neighboring rectal compartment, as reported previously with vaginal administration of the 907 
experimental entry inhibitor CMPD167 using aqueous gels and VRs [158].   908 
 909 
IPM and clinical trial partner the Microbicide Trials Network (MTN) are currently conducting 910 
two Phase III long-term safety and efficacy studies of the monthly DPV ring as part of IPM's 911 
DPV Ring Licensure Program, with efficacy results expected as soon as early 2016 (Table 6). 912 
The Ring Study, started in April 2012 and conducted by IPM, enrolled 1,959 HIV-negative 913 
women aged 18 to 45 across seven research centers in South Africa and Uganda. The ASPIRE 914 
study, started in August 2012 and conducted by MTN, enrolled 2,629 HIV-negative women aged 915 
18 to 45 across 15 sites in Malawi, Uganda, South Africa and Zimbabwe. In both trials, women 916 
were randomly assigned to use the monthly Ring-004 or placebo rings for at least one year.  917 
Results of both studies will be reported early 2016. 918 
 919 
2.7. Combination microbicide and multipurpose prevention technology (MPT) rings 920 
HAART for treatment of HIV/AIDS involves the use of ARV combinations. By using drugs from 921 
different therapeutic classes and with different mechanisms of action, the virus is targeted at 922 
multiple stages of the infection/replication cycle, which can increase the breadth of activity and 923 
reduce the propensity for emergence of resistant viral strains [159–162]. It is rational to extend 924 
this combination strategy to ARV-based vaginal microbicides [163,164]. A combination of 925 
emtricitabine (a nucleoside reverse transcriptase inhibitor) and TDF (a nucleotide analogue 926 
reverse transcriptase inhibitor) administered orally has already been shown to confer HIV 927 
protection in men who have sex with men [165] and the same combination was investigated as 928 
part of the VOICE trial [166]. 929 
 930 
A number of combination microbicide VRs are in the early stages of preclinical / clinical 931 
development. Following on the heels of the DPV Ring-004 are second-generation formulations 932 
containing DPV in combination with maraviroc (MVC) [80,157], darunavir (DRV) [81] and TFV 933 
[43]. MVC is an entry inhibitor ARV that binds the CCR5 co-receptor and prevents the cell entry 934 
of the most frequently transmitted HIV-1 strains [167–170]. It is considered a highly promising 935 
microbicide candidate because of its activity against HIV strains resistant to other ARVs and its 936 
use as a component of current HAART regimes. Aqueous vaginal gel formulations of MVC have 937 
previously been shown to prevent the vaginal transmission of SHIV-162P3 to macaques 938 
[171,172], and subsequent PK testing of the gels in macaques has helped define the local 939 
concentrations required for protection [158,173]. The first report of a MVC-only VR formulation 940 
demonstrated that pretreatment of macaques with Depo-Provera (a subdermal injectable 941 
contraceptive) significantly modified biodistribution of the drug [96]. Following a 2008 licensing 942 
agreement with Pfizer (now ViiV Healthcare), IPM is developing MVC as a microbicide, initially 943 
as a combination with DPV in a matrix-type ring device. Results from the MTN-013/IPM026 944 
clinical study (a multisite PK/pharmacodynamics (PD) study among 48 women of silicone 945 
elastomer VR containing 25 mg DPV, 100 mg MVC, both DPV and maraviroc, or placebo; Table 946 
6) showed that (i) MVC vaginal fluid concentrations in both the maraviroc-only arm and the 947 
combination arm were 2–10 times lower than DPV levels (despite the higher initial drug 948 
loading), (ii) cervical tissue levels of MVC were mostly below the limit of quantification, and 949 
(iii) no in vitro HIV inhibitory activity was observed with the maraviroc cervical tissue samples 950 
[157]. It was concluded that MVC was not released from the rings in sufficient quantities to 951 
provide cervicovaginal concentrations capable of providing protection against HIV transmission. 952 
Previous in vitro testing of the same combination ring device showed that the quantities of DPV 953 
and MVC released from a 25 mg DPV + 100 mg MVC combination matrix-type silicone 954 
elastomer ring were similar [80]. Therefore, the poor release of MVC from the same ring 955 
formulation in the clinical setting is most likely due to physiological constraints placed upon 956 
MVC in the in vivo environment. These could include poor solubility in vaginal fluid, poor 957 
stability in vaginal fluid, poor tissue absorption, and/or rapid elimination from the tissue.  958 
 959 
DRV is a second-generation PI used in combination with other ARVs in the treatment of HIV 960 
infection. PIs inhibit the HIV protease enzyme required to produce mature infectious virus 961 
particles by cleaving structural proteins and enzymes from their precursors. Their high potency 962 
within HAART regimens and the relatively high genetic barrier to the emergence of resistant 963 
HIV strains (compared with other ARVs) suggest they have good potential as microbicides, 964 
administered alone or in combination with other ARVs [174,175]. Preclinical development, 965 
including testing of pharmacokinetics in macaques, has recently been reported for matrix-type 966 
silicone elastomer VRs containing various loadings of DPV and DRV [81]. Serum and vaginal 967 
concentrations of both DPV and DRV in macaques during 28-day ring placement were measured 968 
within the same general range to those reported previously for DPV-only rings in women 969 
[56,76,85,157]. Based on the results of this study, the potential of PIs as vaginal microbicides, 970 
either alone or in combination, warrants further investigation.  971 
 972 
VRs composed of biosoluble acacia gum or a non-biodegradable hydrogel of 2-hydroxyethyl 973 
methacrylate and sodium methacrylate have previously been assessed for formulation of 974 
microbicide combinations, selected from DPV, TFV, AZT and Boc-LBA [66]. A potential issue 975 
with these gum and hydrogel matrices for ring fabrication is their propensity to absorb aqueous 976 
fluids and swell, which could be problematic in vivo. These ring formulations are not being 977 
actively developed. 978 
 979 
The combination microbicide VRs discussed so far have been limited to two ARV drugs 980 
incorporated into the same compartment within the ring device, a strategy previously exploited 981 
with the contraceptive ring Nuvaring in which etonogestrel and ethinyl estradiol are located 982 
within the same core. However, this simple and relatively inexpensive approach to incorporating 983 
multiple drug compounds within a ring also introduces challenges, including increased potential 984 
for drug-drug interactions and reduced ability to independently control the release of each drug. 985 
A formulation strategy to overcome these challenges involves the fabrication of ring devices 986 
having multiple separate compartments, each compartment containing a single drug active. 987 
Several variations on this formulation approach have been reported. Dual-segment rings 988 
comprising DPV incorporated into a hydrophobic polyurethane segment and TFV incorporated 989 
into a hydrophilic polyurethane segment (Figure 5) showed good drug stability and in vitro 990 
release properties [43]. This approach is particularly useful for microbicide molecules having 991 
contrasting hydrophilic/hydrophobic character. 992 
 993 
Despite the fact that a safe and effective vaginal microbicide product has yet to reach market, 994 
there is already considerable interest and early-stage development activity around next-generation 995 
products that combine HIV prevention with contraception and/or prevention/treatment of other 996 
sexually transmitted infections (STIs) and reproductive tract infections. Formulation strategies 997 
for multipurpose prevention technologies (MPTs) are generally based upon the extensive range of 998 
product types available within both the mature contraceptive market and the emerging HIV 999 
microbicide pipeline [48]. Many of the MPT products currently undergoing development have 1000 
prioritised use of LNG as the contraceptive hormone component, based on its historical record of 1001 
safety and effectiveness [46,176,177]. Both DPV and TFV are being developed as MPT rings in 1002 
combination with LNG [61,153]. Clark et al., describe a segmented dual-reservoir polyurethane 1003 
VR (Figure 1G) that delivered the TFV and LNG continuously for 90 days in  a rabbit 1004 
pharmacokinetic model [61]. TFV was incorporated into a hydrophilic polyetherurethane 1005 
reservoir segment in the form of a glycerol paste, while the levonorgestrel was located in a 1006 
separate polyetherurethane reservoir segment. A DPV+LNG VR is also in development, based on 1007 
a similar silicone elastomer matrix-type design to that of the dapvirine-only VR [153]. 1008 
 1009 
A number of MPT VR prototypes containing ZA in combination with the ARV agent MIV-150, 1010 
the linear sulfated polysaccharide CG and the contraceptive steroid LNG are being actively 1011 
developed by The Population Council (Table 3). A 2014 study by Ugaonkar et al. reported that 1012 
sustained in vitro release of ZA from MIV-150/ZA/CG and MIV-150/ZA/CG/LNG combination 1013 
core-type EVA VRs could be achieved for up to 90 days thus offering the potential for protection 1014 
from HIV-1, HSV-2 and unwanted pregnancy from a single ring device [60]. Results from 1015 
macaque efficacy and pharmacokinetic (PK) studies have also been promising, indicating that the 1016 
ZA combination VR devices are capable of providing protection from SHIV-RT and reducing 1017 
viral shedding of HSV-2 [60]. 1018 
 1019 
3. Challenges moving forward 1020 
3.1. Formulation and delivery of biomacromolecular microbicides  1021 
Small-molecule ARVs are currently the major focus of the microbicide field. However, there is 1022 
some interest in the use of biomacromolecular compounds as vaginal microbicides, including 1023 
proteins (cyanovirin-N, GRFT, 5P12-RANTES), peptides (T-1249, PIE12 trimer, rectrocyclin 1024 
RC-101), monoclonal antibodies (mAbs) (b12, 2F5, 4E10, 2G12, VRCO1) and nucleic acids 1025 
(DNA, short interfering RNA (siRNA). Many of these biopharmaceuticals agents can inhibit 1026 
transmission of HIV and other STIs by either directly targeting the free virus or by blocking the 1027 
host cell receptors [178–180].  1028 
 1029 
Broadly neutralizing mAbs such as b12, 2F5, 4E10 and 2G12 [93,181–185] have shown promise 1030 
due to their high potency, excellent safety profile and their unique ability to be both specific 1031 
whilst having a broad spectrum of action when combined in a multi-antibody formulation 1032 
[178,180]. MABGEL1, a monoclonal antibody gel containing 2F5, 4E10 and 2G12 developed by 1033 
the European Microbicides Programme (EMPRO) was the first reported mAb vaginal product to 1034 
undergo Phase I pharmacokinetic and safety testing. The study demonstrated that daily 1035 
application of up to 50 mg of each Ab was safe over a 12 day period and was able to achieve 1036 
concentrations with the potential to block HIV transmission. However, stability of the mAbs was 1037 
a significant issue for these gel formulations [185]. Until recently challenges regarding 1038 
production costs, production capacity, quality control and safety of biological therapeutics has 1039 
prevented large-scale development and evaluation of mAbs in a microbicidal formulation [178]. 1040 
However, recent advances in the production of mAbs in plants such as Nicotiana benthamiana 1041 
has provided the potential for safe, rapid, cost effective production of N-produced recombinant 1042 
human monoclonal antibodies (N-mAbs) [186].  1043 
 1044 
The first antibody-releasing VR was reported in 1992 [187]. These proof-of-concept VR devices 1045 
formulated using lyophilized antibody particles of bovine serum albumin (BSA) and anti-human 1046 
chorionic gonadotropin (anti-hCG) in thermoplastic EVA demonstrated sustained Ab release for 1047 
up to 30 days and prevented HSV-2 transmission in mice, thus paving the way for future Ab-1048 
releasing ring studies [188,189]. In 2011 Morrow et al., reported that a rod-insert VR device was 1049 
capable of releasing the mAb 2F5 [93]. The ring comprised a silicone elastomer ring body into 1050 
which multiple 2F5-loaded lyophilized hydropropylmethylcellulose (HPMC) gel inserts could be 1051 
placed. In vitro release testing demonstrated that the rod-insert device was capable of delivering 1052 
over 1 mg of 2F5 for a period of up to 100 hr dependent on the lyophilized gel insert formulation. 1053 
These VR devices provided the capability to deliver temperature-sensitive biologically-based 1054 
microbicides as production of the lyophilized gel inserts did not involve the use of high 1055 
temperatures normally associated with polymer ring manufacture [16].  1056 
 1057 
Currently, several antibody-containing VRs are undergoing early preclinical development. In a 1058 
recently reported study by Gunawardana et al., a novel pod-type platinum-catalysed silicone 1059 
elastomer VR demonstrated sustained in vitro delivery of ovine IgG (ov-IgG), a model IgG 1060 
human antibody, over a period of 14 days further confirming that a VR device has the potential to 1061 
provide sustained effective release of antibody-based microbicides [86,92]. Mapp66 is a novel 1062 
multi-antibody microbicide currently under investigation by Integrated Preclinical/Clinical 1063 
Program for HIV Topical Microbicides (IPCP-HTM) in conjunction with Mapp 1064 
Biopharmaceutical Inc. [190]. Mapp66 contains a triple combination of N-mAbs (4E10-N, 1065 
VRCO1-N and HSV8-N) that have the potential to neutralize a range of HIV isolates and prevent 1066 
sexually transmitted HSV-2 infection. Early studies suggest that a mapp66 VR device utilizing 1067 
the Versaring pod-insert technology developed by Auritec Pharmaceutical and Oak Crest Institute 1068 
of Science [86] is capable of efficient intravaginal release of N-Mabs [191].  1069 
 1070 
In addition to monoclonal antibodies, sustained delivery of Llama heavy-chain antibody 1071 
fragments (VHH) have been reported from a rod-type ring device [192]. Similar to the rod-insert 1072 
rings reported by Morrow et al. [93], these VR devices manufactured using silicone elastomers 1073 
were capable of holding multiple HPMC compressed or lyophilized gel antibody tablets. In vitro 1074 
release testing demonstrated effective release of the highly potent HIV-1 entry inhibitor (VHH 1075 
A12) over a 7-day period in concentrations sufficient to offer protection in the vaginal 1076 
environment [192]. 1077 
 1078 
As discussed earlier in this review (see Section 2.6.1.) GRFT, a naturally occurring algal protein 1079 
is also undergoing early preclinical evaluation as a potential virus entry inhibitor against multiple 1080 
STIs including HIV-1, HIV-2 and HSV-2. VR devices containing GRFT in combination with CG 1081 
or MIV-150 are currently under evaluation [119,193].    1082 
 1083 
Whilst these biopharmaceuticals have shown early promise as microbicidal candidates their high 1084 
production costs, stability and formulation issues remain major obstacles for their successful 1085 
development as effective microbicidal products. 1086 
 1087 
3.2. Manufacturing issues and scale up 1088 
A potential disadvantage of silicone elastomer VRs is the increased complexity in scaling the 1089 
elastomer/API mixing processes. Most silicone elastomer VR projects use DAC mixers to 1090 
disperse API into the elastomer base. However, scalability of this equipment limits batch sizes to 1091 
5 kg, thereby requiring totally new classes of mixers to be trialed and validated for anything other 1092 
than early clinical testing. Thermoplastic extrusion processes on the other hand are generally 1093 
scalable provided that the screw geometry and length to diameter ratio of the extruder are 1094 
appropriately matched. Also, given the high output capabilities of hot melt extrusion equipment, 1095 
it is feasible to use the same equipment for early clinical trial product manufacture through to 1096 
commercial scale production by simply increasing manufacturing duration. A particular 1097 
disadvantage associated with thermoplastic extrusion as a manufacturing technique to produce 1098 
VRs is the requirement to cut, bend and weld the extrudate ends to form a full ring; this process is 1099 
complex to automate and ultimately the rate limiting step in the production output. These issues 1100 
are not present for thermoplastic or silicone elastomer rings manufactured via injection molding. 1101 
 1102 
Suppliers of injection molding and extrusion equipment often have limited experience of the 1103 
pharmaceutical industry and hence the requirements of cGMP and stringent quality systems that 1104 
must be employed. Significant investment in partnerships between original equipment 1105 
manufacturers and pharmaceutical stakeholders has been necessary to commission suitable 1106 
equipment. As these manufacturing techniques become more widely adopted by the 1107 
pharmaceutical industry, equipment that is capable of fulfilling cGMP requirements should be 1108 
more readily available across the injection molding and extrusion equipment supply sectors. 1109 
 1110 
Multi-cavity injection mold tooling for production of high volumes of rings per cycle require 1111 
significant detail and technical expertise to ensure that conditions such as pressure and 1112 
temperature are uniformly experienced for each ring cavity. In particular, silicone elastomer mold 1113 
tooling is highly specialized with only a handful of companies worldwide with the expertise to 1114 
machine tools with the significantly higher tolerances required compared to thermoplastic tools.  1115 
Limited choice of contract manufacturing organizations (CMO) with the expertise and capability 1116 
to manufacture either thermoplastic or thermosetting-based VRs has also slowed the progress of 1117 
development of microbicide VR products.  1118 
 1119 
Methods for determining the assay value (drug content) of VRs can be time consuming and 1120 
costly. A method for Process Analytical Testing (PAT) has been proposed using Raman 1121 
spectroscopy for the 25 mg DPV ring currently under development [194,195]. This method 1122 
rotates a manufactured ring whilst the Raman spot is focused on a fixed point providing wide 1123 
area illumination and the results were correlated to provide a prediction of content assay values 1124 
for the ring with good levels of accuracy. 1125 
 1126 
3.3. Cost 1127 
Since the inception of the vaginal microbicide concept in 1990 [12], the cost factor has been 1128 
uppermost in the minds of developers. The impact of the HIV pandemic is greatest in Sub-1129 
Saharan Africa and Asia/Pacific region, where 24.7 million and 4.8 million respectively are 1130 
currently living with HIV/AIDS; Sub-Saharan Africa alone accounts for almost 70% of the 1131 
global total of new HIV infections. Many of the countries within these regions have gross 1132 
domestic product per capita values significantly less that $1000, with major implications for the 1133 
availability and quality of healthcare provision. In order to gain widespread use, HIV microbicide 1134 
products must be affordable to at-risk populations. As with all pharmaceutical products, 1135 
manufacturing costs will comprise a very substantial part of the total cost structure of a 1136 
microbicide product, including the costs of the active pharmaceutical ingredients, formulation 1137 
excipients and product packaging. For the 1% TFV gel tested in the CAPRISA 004 trial, 1138 
manufacturing costs were reported as US$ 0.50 per dose, a significant proportion of which was 1139 
for provision of the plastic applicator [196]. By comparison, microbicidal VRs will be much 1140 
more costly to manufacture, due to increased drug loadings, complexity of product design, 1141 
advanced manufacturing processes and the use of relatively expensive excipients. However, 1142 
unlike gels, for which a new dose needs to be applied either daily or before every act of 1143 
intercourse (depending on the prescribed regimen), microbicide-releasing VRs currently in 1144 
development are intended to be worn continuously for at least 28 days. This longer duration of 1145 
use compared with gels will compensate to some degree for the increased costs of ring 1146 
manufacture. Assuming a fixed manufacturing cost per ring device, extending the duration of ring 1147 
use will result in a proportional lowering of the daily cost of use. IPM is developing 60 and 90-1148 
day versions of their 28-day DPV-releasing ring [153]. Advocates are working with researchers 1149 
and policy makers to make sure that any approved microbicide will be as affordable and 1150 
accessible as possible. For example, efforts are already underway to ensure that manufacturing 1151 
costs of the DPV ring are kept as low as possible.  1152 
 1153 
3.4. Acceptability and Adherence 1154 
Numerous studies have reported high user acceptability of VRs for contraception and estrogen 1155 
replacement therapy [29,30,33–35,39,197–202]. Of particular significance is the strong 1156 
preference for rings over semi-solid systems [34,197] which should hopefully extend to vaginal 1157 
microbicide products, since high levels of user acceptability/satisfaction generally correlate with 1158 
user adherence.  1159 
 1160 
Medication adherence is defined as the extent to which users/patients take their medications as 1161 
prescribed. An estimated 20% to 50% of patients do not take their medications as prescribed and 1162 
are said to be non-adherent or non-compliant with therapy [203,204]. Medication non-adherence 1163 
is a major and growing concern for many current drug therapies, including HAART for the 1164 
treatment of HIV infection [205] and statin medication for chronic coronary artery disease [206]. 1165 
User adherence to vaginal microbicide products in late-stage clinical studies has proved 1166 
problematic, particularly for regimens that require regular daily application (i.e. once-daily 1167 
products) or require timing of application close to coitus (i.e. coitally-dependent products) [207–1168 
209]. The most widely cited example is that for the Phase IIb CAPRISA trial of vaginal TFV gel, 1169 
in which HIV acquisition was reduced by an overall estimated 39% [13,210–212]. However, 1170 
adherence estimates based on vaginal applicator returns indicated that HIV incidence was 54, 38 1171 
and 28% lower in the TFV gel arm for high, intermediate and low adherers, respectively, 1172 
demonstrating unequivocally that high adherence is key to microbicide effectiveness. In fact, it 1173 
has primarily been the growing concern over lack of user adherence to gel-based microbicides in 1174 
clinical studies that has driven the prioritization of ARV-releasing VR products [213,166,214].  1175 
 1176 
It has long been assumed that use of sustained or controlled release delivery systems for vaginal 1177 
administration of microbicides to prevent infection with HIV will lead to increased microbicide 1178 
product adherence, acceptability and efficacy compared with more conventional, coitally-1179 
dependent, vaginal formulations by simplifying use instructions and requiring less user behavior 1180 
[15,16,56,215]. Indeed, based on adherence data from other clinical indications [204,216,217], 1181 
including hormonal contraception for which long-acting depot injections, sub-dermal implants, 1182 
transdermal patches and VRs are available [218,219], the case for sustained/controlled release of 1183 
HIV microbicides is generally well made and widely accepted. Previous studies have reported 1184 
high levels of user adherence to VRs for non-microbicide clinical indications. For example, in a 1185 
3-month study comparing adherence to the contraceptive VR Nuvaring and a daily low-dose oral 1186 
contraceptive pill, ring users were more likely to report perfect use [220]. Surprisingly, given the 1187 
acknowledged importance of adherence, only a very limited number of studies have directly 1188 
addressed the topic of adherence to microbicide VRs [221–223]. 1189 
 1190 
One of the major challenges for the HIV microbicide field is the accurate (and preferably 1191 
quantitative) measurement of adherence in late stage clinical trials [207,215,224]. Generally, 1192 
methods for measuring adherence can be divided into two distinct categories. Direct measures of 1193 
adherence, also referred to as “biomarkers”, are substances or effects whose presence or absence 1194 
indicates that a biological or pharmacological process has occurred in response to a drug [207]. 1195 
Indirect measures of adherence comprise two major sub-categories: “objective measures” and 1196 
“self-report measures”, both reliant on the observations or reports of clinicians, trial participants, 1197 
or others [207,225]. Self-reporting tends to overestimate adherence behavior compared with other 1198 
assessment methods and generally has high specificity but low sensitivity [225]. Some of the 1199 
methods previously reported for assessing adherence to microbicides are specific to a particular 1200 
product type. For example, several advanced vaginal gel applicators have been developed, either 1201 
containing a dye that changes color upon exposure to mucin or that record the date and time that 1202 
the syringe piston is depressed into the applicator barrel [226]. Both Phase III clinical studies for 1203 
the DPV ring – The Ring Study and APSIRE – will attempt to measure women’s adherence to 1204 
the ring by measuring concentrations of DPV in blood and vaginal fluid and testing the residual 1205 
DPV content in rings after 28-day use.  1206 
 1207 
The recording of vaginal temperature offers an alternative and interesting biomarker option for 1208 
monitoring adherence to microbicide-releasing VRs. Boyd et al. recently reported the testing in 1209 
macaques of a vaginally-administered silicone elastomer device fitted with a miniature, battery-1210 
operated, temperature logger [97]. The device responded quickly and accurately to vaginal 1211 
removal and insertion, and produced a regular diurnal temperature pattern comprising higher 1212 
temperatures during daytime activity and lower temperatures during nighttime inactivity 1213 
(matching the diurnal cycle observed in a woman’s basal body temperature). Ring devices fitted 1214 
with temperature loggers could be used to directly monitor user adherence as part of late-stage 1215 
clinical testing. 1216 
   1217 
3.5. Correlating in vitro release with in vivo pharmacokinetics 1218 
Development of in vitro-in vivo correlations (IVIVC) for complex, non-oral, extended release 1219 
products is a long-term aim of many pharmaceutical development programs [227]. The overall 1220 
aim is to reduce the regulatory burden associated with certain pre- and post-approval changes. 1221 
For example, manufacturing process, equipment and site changes can be reduced in the presence 1222 
of a Level A or point-to-point IVIVC. However, developing IVIVC for non-oral extended release 1223 
products is extremely challenging due to the complex nature of the formulations and the 1224 
difficulty in accurately mimicking the in vivo release process with an in vitro method [227]. 1225 
These problems are magnified in the microbicide ring field due to the number of variables about 1226 
which we have limited information and the fact that many of the biological factors will vary 1227 
throughout the hormonal cycle. There is also an awareness of the need to define PK-PD 1228 
relationships for microbicides. This is also beset by challenges due to the unique nature of the 1229 
products [176].  1230 
 1231 
Completed, current and pending clinical studies involving microbicide VRs are presented in 1232 
Table 6. Relatively few candidate microbicide compounds have proceeded to clinical testing in a 1233 
ring device. The current Phase III clinical trials of the DPV 25 mg VR should provide key values 1234 
for the vaginal fluid, tissue and plasma concentrations seen on repeated use in a much larger 1235 
sample of women than has been reported to date [56,75,76]. This information, coupled with 1236 
knowledge of the seroconversion status of trial participants, will help establish the vaginal fluid 1237 
and tissue concentrations necessary for protection with this microbicide in a clinical setting. More 1238 
generally, how well these data relate to in vitro IC50 values may also prove informative, giving an 1239 
indication of how close in vitro estimates of activity are to the clinical scenario. However, 1240 
because of the large differences between candidate microbicides physicochemical properties and 1241 
mechanisms of action, other microbicide compound will need to be assessed individually [176]. 1242 
 1243 
The PK of DPV released from IPM’s reservoir-type Ring-002 and matrix-type Ring-003 have 1244 
been compared [56,153]. (The ring designs and silicone elastomer type used in these rings are not 1245 
the same as for the Ring-004 design currently being tested in Phase III [153].) The matrix ring led 1246 
to increased vaginal fluid and plasma levels compared with reservoir ring, although inter-subject 1247 
variability was significantly lower for the reservoir ring. Interestingly, the vaginal fluid 1248 
concentration profiles measured did not reflect the differences typically observed in vitro with 1249 
these rings. The other microbicide tested clinically from a ring device is ACV. A ring containing 1250 
64 mg ACV was found to provide comparable cervicovaginal lavage concentrations over 7 or 14 1251 
days use, to samples provided 2 hr after oral valaciclovir ingestion [90].  1252 
 1253 
Several attempts have been made to correlate in vitro release with that observed in different 1254 
animal models. A selection of published non-human studies involving microbicide releasing VRs 1255 
are presented in Table 7. Overall, these studies have provided some evidence for the development 1256 
of IVIVC in animal species but whether and how this will translate to humans is unclear. First 1257 
attempts at IVIVCs have been published for TFV and ACV release from pod-insert rings into 1258 
rabbits and sheep [89], and for double and triple combination microbicide release (TDF, 1259 
emtricitabine and MVC) in macaques [228].   1260 
 1261 
Several articles have reported a lack of correlation between the in vitro and in vivo release rates. 1262 
For example, in vitro release rate of UC781 was much higher than that observed in vivo, 1263 
presumably attributed to the exceptionally poor water solubility of UC781 [79,229]. It has been 1264 
reported that non-sink in vitro conditions exhibiting partition-controlled release better predicted 1265 
the total amount of experimental pyrimidinedione microbicides released from polyurethane VRs 1266 
in pigtail macaques, whereas sink in vitro release conditions, exhibiting typical matrix-type 1267 
kinetics, over predicted release [83]. In vitro release of MVC and CMPD167 from silicone 1268 
elastomer rings into simulated vaginal fluid (SVF) was a relatively good predictor of the amount 1269 
released in rhesus macaques in vivo [96]. Notably, this work also highlighted the differences 1270 
observed in vivo with the use of depot medroxyprogesterone acetate (DMPA) pre-treatment and 1271 
the impact this can have on measured absorption. Release of the more hydrophobic MC1220 1272 
from matrix-type silicone elastomer rings in macaques was somewhere between that measured in 1273 
vitro into a mixture of equal parts of propan-2-ol and water or SVF [69]. Other researchers have 1274 
found conflicting results between in vitro and in vivo testing in animal models. For example, the 1275 
in vivo concentrations of MIV-150 in vaginal fluids were similar when the microbicide was 1276 
released from both silicone and EVA rings, despite the EVA rings having a higher drug loading 1277 
and showing higher in vitro release rates [77].  1278 
 1279 
Recently deterministic models of vaginal distribution of drugs delivered from both gels and rings 1280 
have been presented [230]. Methods used to determine vaginal drug permeation have also 1281 
recently been reviewed [231]. Given the highly complex and variable nature of the vaginal 1282 
environment and the relative simplicity of the currently used in vitro release rate tests, it may 1283 
prove difficult to effectively correlate values from one to another. However, it may be possible to 1284 
draw some broad inferences from a given release rate test in relation to available clinically tested 1285 
products, as attempted in Table 8 for vaginal fluid concentrations, plasma concentrations and in 1286 
vitro release data of DPV during use of the 25 mg VR. Available data for the same ring tested in 1287 
sheep are presented as are data for a smaller macaque sized ring with the same 25 mg loading, 1288 
composed of similar but not identical type of silicone. This table is informative if merely to show 1289 
the large range of values that may be seen between in vitro release rates and those measured in 1290 
vaginal fluid at any time. 1291 
 1292 
In the first instance, the primary aim of such correlations should be to link previously established 1293 
in vitro release rates with consistently achieved protective vaginal fluid and tissue levels in the 1294 
compartments of interest. It might then be possible to tie together in vitro release rate testing, 1295 
clinical PK profiles and ex vivo assays including challenge assays to provide a more holistic 1296 
picture of drug loadings and release profiles necessary to afford protection. However, all of the 1297 
above in vitro tests will need to be benchmarked against clinical concentration and effectiveness 1298 
data. The ultimate usefulness of IVIVC may only be seen when sufficient clinical data is 1299 
available to allow such comparisons to be drawn. 1300 
 1301 
4. Conclusions  1302 
The past ten years has witnessed unprecedented advances in vaginal ring technology for the 1303 
delivery of drugs, driven almost exclusively by the development of practical, long-acting and 1304 
user-friendly vaginal microbicide products for prevention of sexual transmission of HIV. 1305 
Considerable innovation in the develoment of novel ring designs has emerged in attempts to 1306 
achieve clinically effective release rates for microbicide candidates that often possess very 1307 
different physicochemical properties from the small molecular weight hydrophobic steroid 1308 
molecules for which the original vaginal ring devices were first described back in the 1970s. The 1309 
future of vaginal microbicide VRs will likely depend on the outcome of ongoing clinical studies 1310 
testing dapvirine and tenofovir-releasing rings. In particular, success of the monthly dapivirine 1311 
ring in two recently completed Phase III studies (‘The Aspire Study’ and ‘The Ring Study’) is 1312 
likely a prerequisite for the future viability of not only vaginal ring strategies for HIV prevention, 1313 
but for vaginal microbicides in general. If the key indicators for success are met – at least 1314 
moderate protection against HIV infection; long-term safety; ease of use; user acceptability; good 1315 
user adherence; globlal access – microbicide-relesing VRs are positioned to make a valuable 1316 
contribution in the fight against one of the greatest threats to women’s health globally. Success 1317 
should also stimulate priority development of next-generation combination microbicide and MPT 1318 
VR products aimed at further enhancing protection, minimising development of resistant HIV 1319 
strains, and additionally offering contraception and protection against other STIs.     1320 
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  1966 
 1967 
 1968 
Figure 1. Summary timeline describing key moments, and particularly major clinical activities 1969 
(study start dates), in the development of HIV microbicides. Red boxes represent clinical studies 1970 
that reported an increase in HIV acquisition with use of the microbicide test product. Orange 1971 
boxes represent trials in which the microbicide test product showed no protective effect. Green 1972 
box represents a microbicide test product that offered moderate protection. White boxes at the 1973 
right of the figure represent studies that are ongoing. CS – cellulose sulfate; FHI – Family Health 1974 
International (now FHI 360); IPM – International Partnership for Microbicides; MDP – 1975 
Microbicides Development Programme; MTN – Microbicides Trial Network; N9 – nonoxynol-9.   1976 
 1977 
 1978 
Figure 2. Full ring (upper) and cross-sectional (lower) views of the various vaginal ring designs 1979 
reported in the scientific literature for the delivery of HIV microbicides. Dark shading represents 1980 
the location of the active agent(s).    1981 
 1982 
Figure 3. Curing reaction for condensation-cure silicone elastomer systems.  1983 
 1984 
 1985 
Figure 4. Representation of the platinum-catalysed hydrosilylation reaction for cure of addition-1986 
cure silicone elastomer systems.  1987 
 1988 
Figure 5. General synthetic reactions and representative chemical structures for (A) 1989 
poly(ethylene)-co-vinyl acetate (EVA) polymers and (B) polyurethanes used in the fabrication of 1990 
thermoplastic vaginal rings.    1991 
 1992 
 1993 
Figure 6. Representative daily and cumulative drug release vs. time profiles for non-degradable, 1994 
non-swelling matrix-type and reservoir-type vaginal rings. Matrix-type rings contain crystalline 1995 
drug distributed throughout the entire ring body and exhibit root time kinetics. Here, reservoir 1996 
rings can refer to either a conventional reservoir-type ring comprising one or more drug cores 1997 
encapsulated by a non-medicated membrane (Figure 2 D–G), a core-matrix ring (Figure 2 J) or a 1998 
pod insert type ring (Figure 2 K), all of which display (pseudo) zero-order drug release kinetics.    1999 
 2000 
Figure 7. Representative steps in the manufacturing process for fabrication of silicone elastomer 2001 
vaginal rings. 2002 
  2003 
 2004 
Figure 8. Representative steps in the manufacturing process for fabrication of thermoplastic 2005 
vaginal rings.  2006 
Table 1. Representative composition of the base material for an addition-cure silicone elastomer 2007 

































   
  2010 
Table 2. Representative Part A and B formulation components of addition-cure silicone elastomer 2011 
system used in the fabrication of vaginal rings.  2012 
 2013 
Component Representative chemical structure Part 
silicone elastomer 
base 










inhibitor (used to 





Table 3. Summary of non-ARV HIV microbicide candidates that have been formulated in vaginal ring devices. 2016 
 2017 
Microbicide Candidates / 
APIs 














Zinc acetate, carrageenan 
(ZC) 






Core / EVA ✓ ✓ ✓  Population Council 
Advanced 
Preclinical 
Zinc acetate, MIV-150, 
LNG (MZL) 
Core / EVA ✓   ✓ 
Population Council 





Core / EVA ✓ ✓ ✓ ✓  Early Preclinical 
Boc-lysinated betulonic 
acid (Boc-LBA) 
Reservoir /  
Bio-soluble 
acacia gum 
✓    
Weill-Cornell 




betulonic acid, ferrous 







✓   ✓ Biorings LLC Early Preclinical 
Griffithsin n/a ✓ ✓ ✓  Population Council Early Preclinical 
Table 4. Summary of antiretroviral drugs that have been formulated in vaginal rings as HIV 2018 
microbicides.  ENT – entry inhibitor; INT – integrase inhibitor; NNRTI – non-nucleoside reverse 2019 




































































































Table 5. Summary of vaginal rings reported for the delivery of tenofovir (TFV) or tenofovir disoproxil fumarate (TDF). Abbreviations: 2023 
ACV – acyclovir; E2 – estradiol; ETN – etonogestrel; LNG  – levonorgestrel; NVP – nevirapine; PK – pharmacokinetic; SQV – 2024 
saquinavir; TPU – polyurethane.  2025 
 2026 
Drug(s) Vaginal ring type Materials Image Study details Reference 




in vitro characterization of 
dual segment 
polyurethane VRs; 30 day 




reservoir (tubing) filled 





in vitro characterization; 
PK testing in sheep; 90 
day of TFV achieved  
[83]  
TFV + ACV pod (multiple) 
silicone elastomer ring 
body; polylactic acid-
coated pellets  
 
in vitro characterization; 
28 day of both TFV and 
ACV achieved 
[86]  
TFV and TDF pod (×2) 




28-day PK study in sheep; 
tissue levels of TDF were 
86-fold higher than TFV  
  
[88] 
TFV + ACV pod (×4) 




in vitro characterization; 
28-day PK evaluation in 
rabbits and sheep 
[89] 
TFV pod (×4) 




in vitro characterization; 
safety and 28-day PK 
evaluation in pig-tailed 
macaques   
[87] 
TDF matrix 
hydrophilic TPU; EVA; 
silicone elastomer 
 
in vitro characterization, 
including testing in cell 
and explant models  
 
[62]  
TFV matrix PLA and EVA blends 
 
in vitro characterization [151] 
TFV + NVP + 
SQV + E2 + 
ETG 
pod (×10) 




28-day PK study in sheep; 
demonstration that five 




TFV matrix PCL 
 
in vitro characterization [68] 
TDF 
matrix; reservoir 
(tubing) with solid TDF 
± solid excipients  
hydrophilic TPU 
 
in vitro characterization; 
multiple low-dose SHIV 




TDF reservoir NA 
 
6-month safety and PK 
study in pig-tailed 
macaques 
[152]  
TFV + LNG dual-segment reservoir hydrophilic TPU 
 
in silico, in vitro and in 
vivo (rabbit) evaluation 
[61] 
 2027 
Table 6. Completed, ongoing and planned microbicide vaginal ring clinical trials. Abbreviations 2028 
used in table: DPV – dapivirine; IPM – International Partnership for Microbicides; FTC – 2029 
emtricitabine; PK – pharmacokinetics; LNG – levonorgestrel; MTN – Microbicide Trials 2030 
Network; MPT – multipurpose prevention technology; MVC – maraviroc; TDF – Tenofovir 2031 
disoproxil fumarate; TFV – tenofovir. 2032 
 2033 
Trial Description Phase Countries No. women Status 
IPM 001 
DPV ring safety (Ring-
001) 
1 Belgium 12 Completed 
IPM 008 
DPV ring safety (Ring-
002) 
1 Belgium 13 Completed 
IPM 011 
Placebo ring safety & 
acceptability 
n/a 
South Africa / 
Tanzania 
170 Completed 
IPM 013 DPV ring PK (Ring-004) 1 Belgium 48 Completed 
IPM 015 








DPV ring PK (Ring-002 & 
Ring-003) 
1 Belgium 24 Completed 
IPM 024 DPV ring PK (Ring-004) 1 Belgium 16 Completed 
IPM 026 / 
MTN 013 
MVC, DPV, and DPV-
MVC combination rings 
1 USA 48 Completed 
IPM 027 
‘The Ring Study’ – DPV 







DPV ring drug-drug 
interaction (Ring-004) 
1 Belgium 36 Completed 
IPM 029 
DPV ring & male condom 
functionality (Ring-004) 
n/a USA 70 couples Completed 
IPM 030 / 
MTN 023 
DPV ring safety (Ring-
004) 
2a USA 96 Ongoing 
IPM 031 / 
MTN 024 
DPV ring safety and 
acceptability (Ring-004) 
2a USA 96 Ongoing 
IPM 033 
DPV ring and female 
condom functionality 
(Ring-004) 
n/a USA 80 couples 
Study report 
in progress 
IPM 034 DPV ring PK (Ring-004) n/a Belgium 40 Completed 
IPM 035 
DPV ring & menses and 
tampon use (Ring-004) 
n/a Belgium 32 Ongoing 
IPM 036 
DPV ring drug-drug 
interaction (Ring-004) 
1 Belgium 36 Ongoing 
  2034 
MTN 020 
ASPIRE – DPV ring 












Combination MPT ring 
containing DPV+LNG 




TDF ring / safety and PK 
(IVR-001) 
1 USA 30 Completed 
CONRAD 
TFV-only ring and TFV+ 







TDF-only, TDF+FTC and 
TDF+FTC+MRV rings / 
Safety and PK 
0 USA 6 Ongoing 
MTN 027 / 
NIAID 
MPT rings containing 
Vicriviroc and MK-2048A / 
Safety and PK 
1 USA 48 Recruiting 
MTN 028 / 
NIAID 
MPT rings containing 
Vicriviroc and MK-2048A / 
PK 
1 USA 18 Recruiting 
Population 
Council 
MPT ring containing 
griffithsin 
1 n/a n/a 
Planned 
(2017/18) 
Table 7. List of published articles describing animal testing of microbicide vaginal rings. 2035 
 2036 
Animal species Compound(s) tested Reference 
Macaque (cynomolgus) DPV + DRV [81] 
Macaque (pigtail) 
IQP-0528; IQP-0532 [232] 
TDF [63,84,152] 
TDF + FTC + MVC [228] 
UC781  [229]  
Macaque (rhesus)  
CMPD167  [96,158]  
MC1220 [69] 
MIV-150 [77,233,234] 
MIV-150 + ZA + CG + LNG [60] 
MIV-160  [78]  
MRV [96]  
Rabbits 
TFV + ACV [89] 
TFV + LNG [61] 
UC781 [79]  
Sheep 
DPV [156] 
TFV; TDF  [83,88] 
TFV + ACV [89] 
TFV + NVR + SQN + ETN + 
EST 
[91] 
  2037 
Table 8. Values for the vaginal fluid and plasma/serum concentration of DPV at various time points after 2038 





4 8 15 22 
Plasma/serum  
(pg/mL) 
Humana 299 357 357 327 
Sheepb 58 59 37 32 
Macaquec,d 164 94 78 110 
Vaginal fluid  
(µg/g) 
Humana 44 45 44 37 
Sheepb 4.2 2.6 1.7 1 
Macaquec,d 3.7 6.1 6 4.9 
In vitro daily  
release (µg/day)e 
Human ring 684 425 273 212 
Macaque ring 416 278 201 156 
 2042 
a Values estimated from published graphs of plasma and vaginal fluid concentration against time; weighted by the number of 2043 
participants [75,76] 2044 
b Values estimated from published graphs of plasma and vaginal fluid concentration against time [156] 2045 
c Values interpolated from concentrations measured at time points either side of the time in question [81] 2046 
d Macaque sized rings (25×6 mm) utilising an alternative platinum catalysed silicone were used. 2047 
e In vitro release was measured into IPA:H2O, 100 mL for human sized rings, 50 mL for macaque rings. 2048 
